

The logo for Justia, featuring the word "JUSTIA" in white, bold, uppercase letters inside a black rectangular box.

Canine coronavirus S gene and uses therefor

Jan 28, 2000 - Pfizer Inc.

The present invention provides the amino acid and nucleotide sequences of a CCV spike gene, and compositions containing one or more fragments of the spike gene and encoded polypeptide for prophylaxis, diagnostic purposes and treatment of CCV infections.

Latest Pfizer Inc. Patents:

- N-SUBSTITUTED-DIOXOCYCLOBUTENYLAMINO-3-HYDROXY-PICOLINAMIDES USEFUL AS CCR6 INHIBITORS
- ORAL SOLUTION FORMULATION
- STABILITY-MODULATING LINKERS FOR USE WITH ANTIBODY DRUG CONJUGATES
- Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof
- COMBINATION PRODUCT FOR THE TREATMENT OF CANCER

Skip to: [Description](#) · [Claims](#) · [References Cited](#) · [Patent History](#) · [Patent History](#)

Description

CROSS-REFERENCE TO RELATED APPLICATION

This is a continuation of allowed U.S. application Ser. No. 08/331,625, now U.S. Pat. No. 6,057,436 filed Nov. 23, 1994, itself the U.S. national stage of PCT/US93/04692, filed May 7, 1993, which is a continuation-in-part of U.S. patent application Ser. No. 07/880,194, filed May 8, 1992 now abandoned which is a continuation-in-part of U.S. patent application Ser. No. 07/698,927, filed May 13, 1991, now abandoned which is a continuation-in-part of U.S. patent application Ser. No. 07/613,066, filed Nov. 14, 1990 now abandoned.

FIELD OF THE INVENTION

The present invention relates generally to canine coronavirus infections, and specifically to proteins useful in prophylaxis, therapy, and diagnosis of these infections in canines.

BACKGROUND OF THE INVENTION

The coronaviruses are a large family of mammalian and avian pathogens which were first described in 1968. They are the causative agents of several diseases including encephalitis, hepatitis, peritonitis and gastroenteritis. Enteric coronaviruses have been detected in the feces of man, pigs, calves, cats, mice, chickens and dogs.

Canine coronavirus (CCV) enteritis was first isolated from dogs suffering an acute gastroenteritis, as reported by Binn et al., Proc. 78th Ann. Mtg. U.S. Animal Health Assoc., Roanoke Va., pp. 359-366 (1974). The disease became prevalent during the 1970s. CCV gastroenteritis appears to be primarily transmitted through fecal contamination from infected dogs via the oral route, leading ultimately to replication of the virus in the epithelial cells of the small intestine. Virus can be recovered from the feces of an infected dog between 3 and 14 days after infection.

CCV gastroenteritis is characterized by a mild depression, anorexia and loose stool from which the dog usually recovers. The onset of the disease is often sudden, accompanied by such symptoms as diarrhea, vomiting, excreted blood in stools, and dehydration. Deaths have occurred within as little as 24 to 36 hours after onset of clinical signs. Most dogs appear afebrile but elevated body temperature is seen in some cases. Often CCV will occur with a canine parvovirus infection and this coinfection can be fatal.

Serologically the disease is closely related to transmissible gastroenteritis virus of swine (TGEV). Although canine coronavirus does not infect pigs, transmissible gastroenteritis virus produces a subclinical infection in dogs. However, unlike the feline infectious peritonitis coronavirus (FIPV), previous exposure to CCV does not predispose dogs to enhanced disease; and antigen-antibody complexes, if formed, are not associated with disease pathology.

There remains a need in the art for compositions useful in diagnosing, treating and preventing infections with canine coronaviruses.

SUMMARY OF THE INVENTION

In one aspect the present invention provides the complete nucleotide sequence of the CCV S gene, strain 1-71, SEQ ID NO:1. The S gene or fragments thereof may be useful in diagnostic compositions for CCV infection.

In another aspect the present invention provides a CCV S (or spike) protein characterized by the amino acid sequence of a CCV S protein, SEQ ID NO:2, and peptide fragments thereof. These proteins may be optionally fused or linked to other fusion proteins or molecules.

Thus, in another aspect, the present invention provides a vaccine composition containing an effective immunogenic amount of at least one CCV S protein or an immunogenic fragment thereof.

In still another aspect, the invention provides a method of vaccinating an animal against infection with a coronavirus by administering an effective amount of a vaccine composition of this invention.

In yet a further aspect, the present invention provides a pharmaceutical composition for the treatment of CCV infection comprising a therapeutically effective amount of a CCV S peptide or protein of the invention and a pharmaceutically effective carrier.

Still another aspect of this invention is an antibody directed to CCV, which antibody is capable of distinguishing between CCV and other canine viruses. These antibodies may also be employed as diagnostic or therapeutic reagents.

In yet another aspect, a diagnostic reagent of the present invention comprises a CCV S protein or fragment thereof. In another aspect, the present invention provides a diagnostic reagent which comprises a nucleotide sequence which encodes a CCV S protein or fragment of the invention, and/or a nucleotide sequence which flanks the coding region, or fragments thereof. These protein and nucleotide sequences are optionally associated with detectable labels. Such diagnostic reagents may be used to assay for the presence of CCV in dogs using standard assay formats and can form components of a diagnostic kit.

In a further aspect, the invention provides a method of using a diagnostic reagent of this invention to identify dogs which are uninfected or which have been previously exposed to CCV. The diagnostic method can differentiate exposure to CCV from exposure to other related

coronaviruses, allow the identification of dogs which have been vaccinated against these diseases, and allow one to distinguish between different strains of CCV, or to identify dogs at advanced stages of CCV infection.

In yet a further aspect, the invention provides a method for the production of a recombinant CCV protein comprising culturing a selected host cell, e.g., a mammalian cell or viral vector, transformed with a DNA sequence encoding a selected CCV S protein or fragment thereof in operative association with regulatory sequences capable of regulating the expression of said protein.

Another aspect of the invention is a recombinant DNA molecule comprising a DNA sequence coding for a selected portion of a canine coronavirus S protein, the DNA sequences in operative association with regulatory sequences capable of directing the expression thereof in host cells.

Other aspects and advantages of the present invention are described further in the following detailed description of the preferred embodiments thereof.

DETAILED DESCRIPTION OF THE INVENTION

The present invention provides novel isolated canine coronavirus (CCV) S proteins and fragments thereof, as well as isolated nucleotide sequences encoding the proteins or fragments. These proteins and fragments are useful for diagnostic, vaccinal and therapeutic compositions as well as methods for using these compositions in the diagnosis, prophylaxis and treatment of CCV-related and other coronavirus-related conditions.

I. Definitions

As defined herein, an amino acid fragment is any amino acid sequence from at least about 8 amino acids in length up to about the full-length CCV S gene protein. A nucleotide fragment defines a nucleotide sequence which encodes from at least about 8 amino acids in length up to about the full-length CCV S gene protein.

The term “region” refers to all or a portion of a gene or protein, which may contain one or more fragments as defined above.

The term “immunogenic” refers to any S gene protein or fragment thereof, any molecule, protein, peptide, carbohydrate, virus, region or portion thereof which is capable of eliciting a protective immune response in a host, e.g., an animal, into which it is introduced.

The term “antigenic” refers only to the ability of a molecule, protein, peptide, carbohydrate, virus, region or portion thereof to elicit antibody formation in a host (not necessarily

protective).

As used herein, the term “epitope” refers to a region of a protein which is involved in its immunogenicity, and can include regions which induce B cell and/or T cell responses.

As used herein, the term “B cell site or T cell site” defines a region of the protein which is a site for B cell or T cell binding. Preferably this term refers to sites which are involved in the immunogenicity of the protein.

II. Sources of CCV Sequences

The examples below specifically refer to newly identified spike gene sequences from canine coronavirus (CCV) strain 1-71. This strain is deposited with the American Type Culture Collection (ATCC), 12301 Parklawn Drive, Rockville, Md. under Accession No. VR-809. Particularly disclosed are nucleotide and amino acid sequences, SEQ ID NO:1 and 2, respectively, of the CCV S gene.

The present invention is not limited to the particular CCV strain employed in the examples. Other CCV strains have been described, e.g., strain CCV-TN449 [ATCC 2068]. Utilizing the teachings of this invention, analogous fragments of other canine coronavirus strains can be identified and used in the compositions of this invention.

II. CCV Nucleotide and Amino Acid Sequences of the Invention

The inventors have identified and selected nucleotide and protein sequences of CCV strain 1-71 which have been determined to be of interest for use as vaccinal, therapeutic and/or diagnostic compositions. For example, selected peptide and nucleotide sequences present primarily in the variable N terminal region of the CCV S protein and gene are characterized by representing areas of homology between FIPV, TGEV, feline enteric coronavirus (FECV) and other coronavirus strains.

Peptide fragments obtained from this heterogeneous N terminal of the S protein are useful fragments for diagnostic compositions and kits for distinguishing between infection with CCV strain 1-71 from other CCV infections, and for distinguishing between infection with CCV and other coronavirus identified above in a vaccinated or infected dog, as well as for use in vaccine and therapeutic agents.

Additionally, the amino terminal sequences of CCV S protein include peptide sequences which are B cell sites and thus useful in vaccinal or therapeutic compositions, or for generating antibodies to CCV, in assays for the detection of CCV antibodies in dogs.

In addition, certain peptide fragments of the CCV S protein are believed to represent T cell sites, and thus are useful in vaccinal or therapeutic compositions.

Other suitable CCV amino acid regions for pharmaceutical or diagnostic use are located within other regions of the CCV S protein SEQ ID NO: 2. These amino acid and nucleotide fragments of the CCV S protein and its nucleotide sequence discussed above are specifically reported below in Tables I and II. Table II also reports the respective homologies of certain of these desired fragments to wild-type FIPV, i.e., FIPV WSU 1146. The CCV S nucleotide fragments in Tables I and II can be useful for diagnostic probes, PCR primers, or for use in recombinant production of relevant S protein fragments for use in therapeutic or vaccinal compositions. Other suitable fragments may also be identified for such use.

TABLE I CCV Amino Acids B cell sites T cell sites SEQ ID NOS: 50-250 3 375-425 4 450-470 5 550-600 6 650-700 7 770-850 8 900-1025 9 1150-1225 10 1250-1452 11 40-47 12 63-81 13 187-191 14 241-274 15 335-341 16 395-428 17 468-494 18 846-860 19 916-952 20 977-992 21 1068-1145 22 1366-1391 23 TABLE II Amino Acid Sequences CCV 1-71 % Homology CCV 1-71 SEQ ID NOS. Amino Acid Nucleotides to WT FIPV WSU 1146 AA Nucl. 1113-1236 3337-3708 100 25 and 24 540-599 1618-1797 93.3 27 and 26 342-388 1024-1164 93.6 29 and 28 137-153 409-459 64.7 31 and 30 375-388 1123-1164 85.7 33 and 32 1424-1440 4270-4320 94.1 35 and 34 1407-1420 4219-4260 85.7 37 and 36 1342-1406 4024-4218 96.9 39 and 38 398-652 1192-1956 93.3 41 and 40 128-555 382-1665 89.5 43 and 42 447-628 1339-1884 91.8 45 and 44

IV. Modified Sequences of the Invention

In addition to the amino acid sequences and corresponding nucleotide sequences of the specifically-recited embodiments of CCV S proteins of this invention, the invention also encompasses other DNA and amino acid sequences of CCV S proteins. Such other nucleic acid sequences include those sequences capable of hybridizing to SEQ ID NO: 1 under conditions of at least 85% stringency, i.e. having at least 85% homology to the sequence of SEQ ID NO: 1, more preferably at least 90% homology, and most preferably at least 95% homology. Such homologous sequences are characterized by encoding a CCV S gene protein related to strain 1-71.

Further, allelic variations (naturally-occurring base changes in the species population which may or may not result in an amino acid change) of DNA sequences encoding the various S amino acid or DNA sequences from the illustrated CCV are also included in the present invention, as well as analogs or derivatives thereof. Similarly, DNA sequences which code for protein sequences of the invention but which differ in codon sequence due to the degeneracies of the genetic code or variations in the DNA sequence encoding these proteins which are caused

by point mutations or by induced modifications to enhance the activity, half-life or production of the peptide encoded thereby are also encompassed in the invention.

Variations in the amino acid sequences of this invention may typically include analogs that differ by only 1 to about 4 codon changes. Other examples of analogs include polypeptides with minor amino acid variations from the natural amino acid sequence of S gene proteins and/or the fusion partner; in particular, conservative amino acid replacements. Conservative replacements are those that take place within a family of amino acids that are related in their side chains. Genetically encoded amino acids are generally divided into four families: (1) acidic=aspartate, glutamate; (2) basic=lysine, arginine, histidine; (3) non-polar=alanine, valine, leucine, isoleucine, proline, phenylalanine, methionine, tryptophan; and (4) uncharged polar=glycine, asparagine, glutamine, cysteine, serine, threonine, tyrosine. Phenylalanine, tryptophan, and tyrosine are sometimes classified jointly as aromatic amino acids. For example, it is reasonable to expect that an isolated replacement of a leucine with an isoleucine or valine, an aspartate with a glutamate, a threonine with a serine, or a similar conservative replacement of an amino acid with a structurally related amino acid will not have a significant effect on its activity, especially if the replacement does not involve an amino acid at an epitope of the polypeptides of this invention.

V. Fusion Proteins

If desired, the CCV S proteins and peptide fragments, e.g. those identified in Tables I and II, can be produced in the form of fusion proteins as defined below. Such a fusion protein may contain either a full-length CCV S protein or an immunogenic fragment thereof. Suitable fragments include those contained within SEQ ID NO: 2 and the amino acids fragments of Tables I and II. Other suitable fragments can be determined by one of skill in the art by analogy to the sequences provided herein.

Proteins or peptides may be selected to form fusion proteins with the selected S protein or peptide sequence based on a number of considerations. The fusion partner may be a preferred signal sequence, a sequence which is characterized by enhanced secretion in a selected host cell system, or a sequence which enhances the stability or presentation of the S-derived peptide. Such exemplary fusion partners include, without limitation, ubiquitin and a mating factor for yeast expression systems, and beta-galactosidase and influenza NS-1 protein for bacterial systems. One of skill in the art can readily select an appropriate fusion partner for a selected expression system. The present invention is not limited to the use of any particular fusion partner.

The CCV S protein or fragments thereof can optionally be fused to each other or to the fusion

partner through a conventional linker sequence, i.e., containing about 2 to 50 amino acids, and more preferably, about 2 to about 20 amino acids in length. This optional linker may provide space between the two linked sequences. Alternatively, this linker sequence may encode, if desired, a polypeptide which is selectively cleavable or digestible by conventional chemical or enzymatic methods. For example, the selected cleavage site may be an enzymatic cleavage site, including sites for cleavage by a proteolytic enzyme, such as enterokinase, factor Xa, trypsin, collagenase and thrombin. Alternatively, the cleavage site in the linker may be a site capable of being cleaved upon exposure to a selected chemical, e.g., cyanogen bromide or hydroxylamine. The cleavage site, if inserted into a linker useful in the fused sequences of this invention, does not limit this invention. Any desired cleavage site, of which many are known in the art, may be used for this purpose.

VI. Production of Sequences of Invention

The CCV S gene protein of the invention and amino acid regions, fragments thereof and their corresponding nucleotide sequences, as well as other proteins described herein, e.g. fusion partners, may be produced by conventional methods. These proteins or fragments and the nucleotide sequences may be prepared by chemical synthesis techniques [Merrifield, J.A.C.S., 85:2149-2154 (1963)]. Preferably, however, they are prepared by known recombinant DNA techniques by cloning and expressing within a host microorganism or cell a DNA fragment carrying a coding sequence for the selected protein. See, e.g., Sambrook et al, "Molecular Cloning. A Laboratory Manual", 2nd edit., Cold Spring Harbor Laboratory, New York (1989). Such techniques are discussed below in the Examples.

According to cloning techniques, a selected gene fragment of this invention can be cloned into a selected expression vector. Vectors for use in the method of producing S protein proteins comprise a novel S gene DNA sequence (or a fragment thereof) of the invention and selected regulatory sequences in operative association with the DNA coding sequence, and capable of directing the replication and expression of the peptide in a selected host cell.

Vectors, e.g., polynucleotide molecules, of the invention may be designed for expression of CCV S proteins and/or fusion proteins in bacterial, mammalian, fungal or insect cells or in selected viruses. Suitable vectors are known to one skilled in the art by resort to known publications or suppliers.

The resulting DNA molecules or vectors containing nucleotide sequences encoding the canine coronavirus S peptides or fragments thereof and/or encoding the fusion proteins are then introduced into host cells and expression of the heterologous protein induced.

Additional expression systems may include the known viral expression systems, e.g., vaccinia,

fowlpox, swine pox. It is understood additionally, that the design of the expression vector will depend on the choice of host cell. A variety of suitable expression systems in any of the below-identified host cells are known to those skilled in the art and may be readily selected without undue effort.

Suitable cells or cell lines for use in expressing the S protein or peptides of this invention can be eukaryotic or prokaryotic. A preferred expression system includes mammalian cells, such as Chinese Hamster ovary cells (CHO) or COS-1 cells. The selection of other suitable mammalian host cells and methods for transformation, culture, amplification, screening and product production and purification are known in the art. See, e.g., Gething and Sambrook, *Nature*, 293:620-625 (1981), or alternatively, Kaufman et al, *Mol. Cell. Biol.*, 5(7) :1750-1759 (1985) or Howley et al, U.S. Pat. No. 4,419,446. Also desirable are insect cell systems, such as the baculovirus or *Drosophila* systems. The selection of other suitable host cells and methods for transformation, culture, amplification, screening and product production and purification can be performed by one of skill in the art by reference to known techniques. See, e.g., Gething and Sambrook, *Nature*, 293:620-625 (1981).

After the transformed host cells are conventionally cultured for suitable times and under suitable culture conditions known to those skilled in the art, the cells may be lysed. It may also be possible, depending on the construct employed, that the recombinant proteins are secreted extracellularly and obtained from the culture medium. Cell lysates or culture medium are then screened for the presence of CCV S protein or peptide which are recognized by antibodies, preferably monoclonal antibodies (MAbs), to a peptide antigenic site from CCV.

Similarly, the fusion proteins may be produced by resort to chemical synthesis techniques, or preferably, recombinant methods, as described above. The selected primer sets used in the PCR reaction described in the Examples below may be designed to produce PCR amplified fragments containing restriction endonuclease cleavage site sequences for introduction of a canine coronavirus s gene fragment in a specific orientation into a selected expression vector to produce fusion proteins of the invention. The vector may contain a desired protein or fragment thereof to which the S gene fragment is fused in frame to produce a fusion protein.

The crude cell lysates containing the CCV S protein or peptides or fusion proteins can be used directly as vaccinal components, therapeutic compositions or diagnostic reagents. Alternatively, the CCV S peptides can be purified from the crude lysate or medium by conventional means.

VII. Vaccine Compositions

The CCV S proteins and immunogenic fragments of this invention may be incorporated in a vaccine composition. Such a vaccine composition may contain an immunogenic amount of one

or more selected CCV S peptides or proteins, e.g., encoded by the complete S gene sequence of CCV or partial sequences thereof, and prepared according to the method of the present invention, together with a carrier suitable for administration as a vaccine composition for prophylactic treatment of CCV infections. The protein may be in the form of a fusion protein as above-described. Alternatively, the CCV S gene or fragment may be incorporated into a live vector, e.g., adenovirus, vaccinia virus and the like. The expression of vaccinal proteins in such live vectors are well-known to those in the art [See, e.g., U.S. Pat. No. 4,920,209]. It is preferable that the protein employed in the vaccine composition induces protective immune responses against more than one strain of CCV.

A vaccine composition according to the invention may optionally contain other immunogenic components. Particularly desirable are vaccine compositions containing other canine antigens, e.g., canine distemper, *Borrelia burgdorferi*, canine Bordetella, rabies, canine parvovirus, *Leptospiridia* sp., canine rotavirus, canine parainfluenza virus and canine adenovirus.

In another embodiment, the cCv S proteins may be used in a combination vaccine directed to related coronaviruses. Other suitable coronaviruses which can be used in such a combination vaccine include a feline coronavirus, such as FIPV or FECV. For example, a CCV S peptide or protein of the present invention may be employed as an additional antigen in the temperature sensitive FIPV vaccine described in detail in co-owned, co-pending U.S. patent application Ser. No. 07/428,796 filed Oct. 30, 1989, incorporated by reference herein. Alternatively, the CCV S protein or peptide or a fragment thereof could be used in a vaccine composition containing other coronavirus S proteins or fragments thereof, particularly those described in co-pending, co-owned U.S. patent application Ser. No. 07/698,927 (and its corresponding published PCT Application No. W092/08487).

The preparation of a pharmaceutically acceptable vaccine composition, having appropriate pH isotonicity, stability and other conventional characteristics is within the skill of the art. Thus such vaccines may optimally contain other conventional components, such as adjuvants and/or carriers, e.g. aqueous suspensions of aluminum and magnesium hydroxides, liposomes and the like.

The vaccine composition may be employed to vaccinate animals against the clinical symptoms associated with CCV. The vaccines according to the present invention can be administered by an appropriate route, e.g., by the oral, intranasal, subcutaneous, intraperitoneal or intramuscular routes. The presently preferred methods of administration are the subcutaneous and intranasal routes.

The amount of the CCV S peptide or protein of the invention present in each vaccine dose is

selected with regard to consideration of the animal's age, weight, sex, general physical condition and the like. The amount required to induce an immunoprotective response in the animal without significant adverse side effects may vary depending upon the recombinant protein employed as immunogen and the optional presence of an adjuvant. Generally, it is expected that each dose will comprise between about 0.05-5000 micrograms of protein per mL, and preferably 0.05-100 micrograms per mL of a sterile solution of an immunogenic amount of a protein or peptide of this invention. Initial doses may be optionally followed by repeated boosts, where desirable.

Another vaccine agent of the present invention is an anti-sense RNA sequence generated to the S gene of CCV strain 1-71 [SEQ ID NO:1] [S. T. Crooke et al, *Biotech.*, 10:882-886 (August 1992)]. This sequence may easily be generated by one of skill in the art either synthetically or recombinantly. Under appropriate delivery, such an anti-sense RNA sequence when administered to an infected animal should be capable of binding to the RNA of the virus, thereby preventing viral replication in the cell.

VIII. Pharmaceutical Compositions

The invention also provides a pharmaceutical composition comprising one or more CCV S peptides or proteins prepared according to the present invention and a pharmaceutically effective carrier. Suitable pharmaceutically effective carriers for internal administration are known to those skilled in the art. One selected carrier is sterile saline. The pharmaceutical composition can be adapted for administration by any appropriate route, but is designed preferentially for administration by injection or intranasal administration.

IX. Antibodies of the Invention

The present invention also encompasses the development of an antibody to one or more epitopes in the above identified amino acid sequences derived from the CCV S protein, which epitope is distinct from those of other CCV strains or other coronaviruses, e.g. FIPV, TGEV or FECV. The antibody can be developed employing as an antigenic substance, a peptide of Table I or II. Alternatively, other regions of the CCV strain 1-71 S protein SEQ ID NO: 2 may be employed in the development of an antibody according to conventional techniques.

In one embodiment, the antibody is capable of identifying or binding to a CCV antigenic site encoded by SEQ ID NO: 1 or a fragment thereof. Such an antibody may be used in a diagnostic screening test, e.g., as a hybridization probe, or as a therapeutic agent.

Antibodies which bind CCV peptides from the regions identified above or to other regions capable of distinguishing between CCV, TGEV, FIPV, FECV, and other coronaviruses for use in

the assays of this invention may be polyclonal. However, it is desirable for purposes of increased target specificity to utilize MAbs, both in the assays of this invention and as potential therapeutic and prophylactic agents. Additionally, synthetically designed MAbs may be made by known genetic engineering techniques [W. D. Huse et al, Science, 2:1275-1281 (1989)] and employed in the methods described herein. For purposes of simplicity the term MAb(s) will be used throughout this specification; however, it should be understood that certain polyclonal antibodies, particularly high titer polyclonal antibodies and recombinant antibodies, may also be employed.

A MAb may be generated by the well-known Kohler and Milstein techniques and modifications thereof and directed to one or more of the amino acid residue regions identified above, or to other CCV S peptides or epitopes containing differences between CCV strain 1-71 and other coronaviruses. For example, a fragment of SEQ ID NO: 2 which represents an antigenic site, which differs from that of FIPV, may be presented as an antigen in conventional techniques for developing MAbs. One of skill in the art may generate any number of MAbs by using fragments of the amino acid residue regions identified herein as an immunogen and employing these teachings.

For diagnostic purposes, the antibodies (as well as the diagnostic probes) may be associated with individual labels. Where more than one antibody is employed in a diagnostic method, the labels are desirably interactive to produce a detectable signal. Most desirably, the label is detectable visually,, e.g. calorimetrically. Detectable labels for attachment to antibodies useful in the diagnostic assays of this invention may also be easily selected by one skilled in the art of diagnostic assays, amount which include, without limitation, horseradish peroxidase (HRP) or alkaline phosphatase (AP), hexokinase in conjunction with glucose-6-phosphate dehydrogenase, and NAD oxidoreductase with luciferase and substrates NADH and FMN or peroxidase with luminol and substrate peroxide. These and other appropriate label systems and methods for coupling them to antibodies or peptides are known to those of skill in the art.

Antibodies may also be used therapeutically as targeting agents to deliver virus-toxic or infected cell-toxic agents to infected cells. Rather than being associated with labels for diagnostic uses, a therapeutic agent employs the antibody linked to an agent or ligand capable of disabling the replicating mechanism of the virus or of destroying the virally-infected cell. The identity of the toxic ligand does not limit the present invention. It is expected that preferred antibodies to peptides encoded by the S genes identified herein may be screened for the ability to internalize into the infected cell and deliver the ligand into the cell.

X. Diagnostic Reagents and Assays

The nucleotide sequences, amino acid fragments and antibodies described above may be employed as diagnostic reagents for use in a variety of diagnostic methods according to this invention.

A. ECR Diagnostic Assays

For example, these sequences can be utilized in a diagnostic method employing the polymerase chain reaction (PCR) technique to identify the presence of a CCV or CCV-like virus and in therapy of infected animals.

In addition to those sequences identified above, the oligonucleotide sequences that were designed to prime cDNA synthesis at specific sites within the CCV S gene, as described in detail below in Example 3 [SEQ ID NO:46-50], may also be employed as diagnostic reagents according to this invention. These sequences, as well as the below-described optimized conditions for the PCR amplification of CCV fragments therefrom, may also be employed in a diagnostic method.

The PCR technique is known to those of skill in the art of genetic engineering and is described in detail in Example 4 [see, e.g., R. K. Saiki et al, *Science*, 230:1350-1354 (1985)], which is incorporated herein by reference. Briefly described, PCR employs two oligonucleotide primers which are complementary to the opposite strands of a double stranded nucleic acid of interest whose strands are oriented such that when they are extended by DNA polymerase, synthesis occurs across the region which separates the oligonucleotides. By repeated cycles of heat denaturation, annealing of the primers to their complementary sequences and extension of the annealed primers with a temperature stable DNA polymerase, millions of copies of the target gene sequence are generated. The template for the reaction is total RNA, which is isolated from CCV infected cells. DNA fragments generated by PCR were amplified from cDNA which had been synthesized from this RNA. Other strains of CCV or CCV-related sequences may also provide PCR templates in a similar manner.

In one diagnostic method, for example, heterogenous CCV gene sequences of this invention are useful as reagents in diagnostic assays to detect and distinguish the presence of specific viruses from each other, e.g., to distinguish one canine coronavirus strain from another or one species of coronavirus from another by means of conventional assay formats. For example, using protocols similar to those used for forensic purposes, tissue or blood samples from a dog suspected to be infected with CCV would be subjected to PCR amplification with a selected CCV-specific set of primers, such as those DNA sequences disclosed herein. Amplification of DNA from a sample tissue or biological fluid of the animal suspected of infection using nucleotide sequences as primers specific for regions of the CCV viral gene sequences could correlate to the

presence of CCV. Absence of CCV in the sample would result in no amplification. Similarly, the selection of specific sets of S gene primers would allow the identification of a particular strain of CCV as well. Thus, appropriate treatments may be selected for the infected animal.

Example 3 provides oligonucleotide primers which permitted the synthesis of regions of the CCV S gene. The nucleotide sequence of the S gene of CCV provides desirable sequences for hybridization probes and PCR primers, for example, the sequences between nucleotide base pairs 900 to about 1600 [SEQ ID NO: 55] and about 2500 to about 3900 [SEQ ID NO: 56] of SEQ ID NO: 1. Smaller or larger DNA fragments in these regions may also be employed as PCR primers or hybridization probes.

It is desirable to have PCR primer sequences between 15 to 30 bases in length, with an intervening sequence of at least 100 bases to as large as 5000 bases there between, according to conventional PCR technology. However, it is possible that larger or smaller sequence lengths may be useful based upon modifications to the PCR technology. In general, in order to achieve satisfactory discrimination, a hybridization or oligonucleotide probe made up of one or more of these sequences would consist of between 15 and 50 bases in length based on current technology.

B. Conventional Assay Formats

The CCV S proteins or peptide fragments may also be employed in standard diagnostic assays which rely on S protein immunogens as targets for sera recognition. The diagnostic assays may be any conventionally employed assay, e.g., a sandwich ELISA assay, a Western blot, a Southern blot and the like. Because a wide variety of diagnostic methods exist and are conventionally known which can be adapted to the use of the nucleotide and amino acid sequences described herein, it should be understood that the nature of the diagnostic assay does not limit the use of the sequences of this invention.

For example, the amino acid sequences encoded by CCV S gene sequences, such as those appearing in Tables I and II above, which may be amplified by PCR, provide peptides useful in such diagnostic assays as ELISA or Western assay, or as antigens for the screening of sera or development of antibodies.

For example, the sequences between about amino acid 1 to about 250 [SEQ ID NO:57], about 450 to about 650 [SEQ ID NO:58], and about 900 to about 1150 [SEQ ID NO:59] of the CCV strain 1-71 S gene protein SEQ ID NO:2, are anticipated to be useful as such antigens. Such peptides can optionally also be used in the design of synthetic peptide coupled to a carrier for diagnostic uses, e.g., antibody detection in sera. Suitable carriers include ovalbumin, keyhole limpet hemocyanin, bovine serum albumin, sepharose beads and polydextran beads.

Such peptide antigens and antibodies to these peptides would react positively with tissue or serum samples of dogs infected with CCV, but negatively with non-CCV infected dogs. These antibodies are discussed in more detail below.

For example, the invention provides a method of using the full length CCV S protein or fragments thereof as diagnostic agents for identifying the presence or absence of antibodies in previously exposed, naive or vaccinated dogs, respectively, as well as for differentiating exposure to CCV from other related coronaviruses. Other S peptides or fusion proteins which show differential reactivity to CCV and other coronavirus sera may also be useful as CCV-specific reagents in ELISA-based screening assays to detect CCV exposure in dogs. Similarly, an S protein or peptide which contains epitopes recognized only by sera from CCV infected dogs or by sera from CCV positive dogs could be employed to distinguish or differentiate among coronavirus infections.

As one assay format, the reactivity of affinity purified CCV S proteins or peptides fragments to canine biological fluids or cells can be assayed by Western blot. The assay is preferably employed on sera, but may also be adapted to be performed on other appropriate fluids or cells, for example, macrophages or white blood cells. In the Western blot technique, the purified protein, separated by a preparative SDS polyacrylamide gel, is transferred to nitrocellulose and cut into multiple strips. The strips are then probed with dog sera from uninfected or infected dogs. Binding of the dog sera to the protein is detected by incubation with alkaline phosphatase tagged goat anti-dog IgG followed by the enzyme substrate BCIP/NBT. Color development is stopped by washing the strip in water.

CCV S protein or fragments thereof may also be used in an ELISA based assay for detecting CCV disease. A typical ELISA protocol would involve the adherence of antigen (e.g., a S protein) to the well of a 96-well tray. The serum to be tested is then added. If the serum contains antibody to the antigen, it will bind. Specificity of the reaction is determined by the antigen absorbed to the plate. With the S protein, only sera from those dogs infected with CCV would bind to the plate; sera from naive or uninfected dogs would not bind.

Similarly, a CCV S protein or peptide which contained epitopes recognized only by sera from CCV-infected dogs or by sera from CCV-positive dogs could be employed to distinguish coronavirus infections. After the primary antibody is bound, an enzyme-labeled antibody directed against the globulin of the animal whose serum is tested is added. Substrate is then added. The enzyme linked to antibody bound to the well will convert the substrate to a visible form. The amount of color measured is proportional to the amount of antibody in the test material. In this manner, dogs infected with CCV can be identified and treated, or dogs naive to the virus can be protected by vaccination.

When used as diagnostic reagents, the primers, probes, peptide antigens, nucleotide sequence encoding or flanking a CCV S protein or fragment of the invention, and antibodies of this invention may be optionally associated with detectable labels or label systems known to those skilled in the art. Such labelled diagnostic reagents may be used to assay for the presence of CCV in dogs in hybridization assays or in the PCR technique as described above.

C. Diagnostic Kits

The assay methods, PCR primers, CCV S nucleotide sequences [SEQ ID NO:1], S proteins and peptides, and antibodies described herein may be efficiently utilized in the assembly of a diagnostic kit, which may be used by veterinarians or laboratories. The kit is useful in distinguishing between CCV infected animals and vaccinated animals, as well as non-exposed dogs, and between CCV-infected animals and animals infected with serologically related viruses, such as other CCV or FIPV, TGEV, and FECV. Such a diagnostic kit contains the components necessary to practice the assays described above.

Thus, the kit may contain a sufficient amount of at least one CCV S protein, fusion protein or peptide fragment, at least one CCV S gene nucleotide sequence or PCR primer pair of this invention, a MAb directed to a first epitope on the CCV S protein (which MAb may be labeled), optional additional components of a detectable labelling system, vials for containing the serum samples, protein samples and the like, and a second MAb conjugated to the second enzyme, which in proximity to the first enzyme, produces a visible product. Other conventional components of such diagnostic kits may also be included.

Alternatively, a kit may contain a selected CCV S protein or peptide, a MAb directed against a selected CCV S peptide fragment bound to a solid surface and associated with a first enzyme, a different MAb associated with a second enzyme, and a sufficient amount of the substrate for the first enzyme, which, when added to the serum and MAbs, provides the reactant for the second enzyme, resulting in the color change.

Other known assay formats will indicate the inclusion of additional components for a diagnostic kit according to this invention.

The following examples illustrate the embodiments of this invention and do not limit the scope of the present invention.

EXAMPLE 1

Isolation of CCV

Canine coronavirus strain 1-71 was isolated in 1971 from military dogs suffering from a viral gastroenteritis by Binn et al., Proceeding 78th Annual Meeting U.S. Animal Health Association, October 1974, p. 359-366. The initial isolate from the feces of the infected dog was grown in tissue culture on the PrDKTCA72 dog cell line [ATCC No. CRL 1542]. The coronavirus strain used in this study was received from the ATCC (ATCC #VR-809, CCV Strain 1-71, Frozen lot#4, Passage 7/PDK, 17 May 1988) and passaged five times on PrDKTCA72.

EXAMPLE 2

RNA Purification

After the fifth passage the infected cells were processed for RNA isolation by infecting a 1700 cc2 roller bottle with a CCV inoculum. The inoculum was prepared by diluting 2.5 &mgr;l of infected fluids from a confluent monolayer into 13.0 mls of media. One ml of this material was used to infect a roller bottle and the cells were grown until they demonstrated a pronounced cytopathic effect at 48 hours. The infected monolayers were harvested and total cytoplasmic RNA was extracted using the guanidinium thiocyanate procedure as described in Chirgwin et al., Biochem., 18:5294 (1979).

EXAMPLE 3

Primers Used for PCR Amplification of CCV SDike Gene Fragments

The primers appearing below in Table III were synthesized conventionally by the phosphoramidite method and gel purified prior to use. Primer #3045 was based on an FECV S gene sequence; and primers #4920, 1923, 2443 and 2600 were based on WT FIPV WSU 1146 sequences.

TABLE III Amplified S Gene Region	Cloned Region	Top Primer	Bottom Primer
1-352 aa # 3045	352-1452 aa # 4920	1-362 aa	128-555 aa # 3045
2443	Primer # DNA Sequence	1923	1-555 aa
[SEQ ID NO:46]	1923 TAAATAGGCCTTTAGTGGACATGCACTTTTCAATTGG	2443	2443
	StuI		
TTAGTAGGCCTGTCGAGGCTATGGGTTGACCATAACCAC	[SEQ ID NO:47]		StuI
2600 CAGATCCCGGGTGTACAATCTGGTATGGGTGCTACAG	[SEQ ID NO:48]		
XmaI 3045 GTGCCCCCGGGTATGATTGTGCTCGTAACTTGCCTCTTG	[SEQ ID NO:49]		
XmaI 4920 AGCACCCATAACCAGATTGTACATCTGCAGTGAAATTAAGATTG	[SEQ ID NO:50]		PstI

EXAMPLE 4

PCR Amplification of CCV S Gene

PCR amplified fragments of CCV S gene were generated using the following procedure. All PCR reagents were supplied by Perkin Elmer-Cetus, Norwalk, Conn. In a final reaction volume of 20 μ l of 1 \times RT buffer (5 \times RT buffer: 250 mM Tris-HCl, pH 8.3, 375 mM KCl, 15 mM MgCl₂), the following components were assembled in RNase-free siliconized 500 μ l microcentrifuge tubes: 1.0 mM of each dNTP, 20 units of RNasin [Promega Corp, Madison, Wis.], 2.5 picomoles of random hexamer oligonucleotides [Pharmacia, Milwaukee, Wis.], 100 picomoles/ μ l solution in TE buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5), 200 units of reverse transcriptase [Superscript RT, Bethesda Research Labs, Gaithersburg, Md.] and 1.0 μ g of respective RNA isolated as described above in Example 3. To avoid pipetting errors and contamination, all solutions were aliquoted from master mixes made with diethyl pyrocarbonate (DEPC) treated water and consisted of all of the reaction components except the RNA which was added last.

The mixture was incubated in a programmable thermal cycler [Perkin-Elmer Cetus, Norwalk, Conn.] at 21° C. for ten minutes followed by 42° C. for one hour then 95° C. for five minutes and finally held at 4° C. until PCR amplification.

Amplification of the cDNA was performed essentially according to the method of R. K. Saiki et al, Science, 230:1350-1354 (1985) using the Taq polymerase. Briefly, to the 20 μ l cDNA reaction mix from above was added 10.0 μ l 10 \times PCR buffer, 1.0 μ l of each upstream and downstream primer previously diluted in water to 30 picomoles per microliter and 2.5 units of Taq polymerase (Perkin-Elmer Cetus, Norwalk, Conn.). Final volume was made up to 100 μ l using DEPC treated water and overlaid with 100 μ l of mineral oil. As above, master mixes were prepared to avoid contamination. The reaction was performed in the Perkin-Elmer Cetus thermal cycler for one cycle by denaturing at 95° C. for 1 minute, annealing at 37° C. for 3 minutes followed by an extension at 72° C. for 40 minutes. This initial cycle increased the likelihood of first strand DNA synthesis. A standard PCR profile was then performed by a 95° C. for 1 minute denaturation, 37° C. for 3 minutes annealing, 72° C. for 3 minutes extension for 40 cycles. A final extension cycle was done by 95° C. for 1 minute denaturation, 37° C. for 2 minutes annealing, 72° C. for 15 minutes extension and held at 4° C. until analyzed.

PCR products were analyzed by electrophoresing 5.0 μ l of the reaction on a 1.2% agarose gel for 16-17 hours. Bands were visualized by ethidium bromide staining the gel and fluorescence by UV irradiation at 256 nm. Photography using Polaroid type 55 film provided a negative that could be digitized for sample distance migration and comparison against markers

run on each gel. The actual sizes of the bands were then calculated using the Beckman Microgenie software running on an IBM AT.

EXAMPLE 5

Cloning of CCV Spike Gene Regions

Cloning procedures were performed substantially as described by Maniatis et al, cited above. Details of the clonings are provided in the following examples. Calf-alkaline phosphatase was from Bethesda Research Labs (Gaithersburg, Md.). Ligation products were transformed into E. coli host strain XL1 Blue [Stratagene Cloning Systems, La Jolla, Calif.]. pBluescript SKnM13-phagemid vector was also obtained from Stratagene Cloning Systems. All restriction enzymes were purchased from New England Biolabs (Beverly, Mass.) or Bethesda Research Labs (Gaithersburg, Md.) and used according to manufacturer's specifications. T4 DNA ligase was received from Boehringer Mannheim Biochemicals (Indianapolis, Ind.). Calf intestinal alkaline phosphatase was purchased from Bethesda Research Labs.

EXAMPLE 6

CCV S Protein Fragment, A.A. 1-128 [SEQ ID NO:51]

Five microliters (approximately 200 ng) of PCR-amplified DNA representing amino acids 1-362 [SEQ ID NO:53] of the CCV spike gene were ligated to the pT7Blue T-Vector (Novagen, Madison, Wis.) as per the manufacturer's instructions. One microliter of the ligation mix was used to transform NovaBlue competent cells (Novagen) and transformation mixes were plated on LB plates supplemented with ampicillin, isopropylthio-β-galactoside (IPTG; Sigma Chemical Co., St. Louis, Mo.), and 5-bromo-4-chloro-3-indolyl-β-D-galactoside (X-gal; Sigma Chemical Co., St. Louis, Mo.). White colonies were picked and screened by restriction analysis of mini-prep DNA. Insert-bearing clones were identified and oriented with respect to vector by SmaI/PstI, StuI, and PstI digests. Clone #2964 contained a full-length 1-362 amino acid insert and was used to provide sequence analysis from 1-128 amino acids of the CCV S gene.

EXAMPLE 7

CCV S Protein Fragment. A.A. 128-555 [SEQ ID NO: 43]

10 μg of PCR DNA encoding 1-555aa of the CCV spike protein was digested with SmaI/StuI

for 4 hours at room temperature. DNA bands were isolated and purified from low-melting temperature agarose gels as described by Maniatis et al, cited above. Briefly, DNA fragments were visualized after staining with ethidium bromide, excised from the gel with a scalpel and transferred to microfuge tubes. Gel slices were incubated 5 min at 65° C., vortexed, and 5 volumes of 20 mM Tris, pH 8.0, 1 mM EDTA were added. Samples were incubated an additional 2 minutes at 65° C. and were then extracted once with phenol and again with phenol:chloroform. The DNA was precipitated with 1/10 volume 3 M NaOAc, pH 7.0, and 2.5 volumes of cold 95% EtOH overnight at -20° C. Insert DNAs were ligated to SKnEM13-SmaI-digested, dephosphorylated vector [Stratagene] for 4 hours at room temperature. Insert-bearing clones were identified by XhoI/SstI and BqII digests of mini-prep DNA. Restriction enzyme and sequence analysis indicated that the cloned insert was short by -300 bp due to the presence of a StuI site at amino acid #128 of the CCV spike gene. Therefore, these clones contained the CCV S protein spanning amino acids from about 128-555 [SEQ ID NO:43].

EXAMPLE 8

CCV S Protein Fragment. A.A. 352-1452 [SEQ ID NO:52]

PCR-amplified DNA fragments encoding amino acids 352-1454 of the CCV spike protein were purified using Prime-Erase Quik Columns [Stratagene] according to the manufacturer's instructions. Column-purified DNAs were then digested with XmaI/EcoRV overnight at 15° C. and subsequently isolated and eluted from low-melting temperature agarose gels as described by Maniatis et al, cited above. Inserts were ligated overnight at 15° C. to SKnM13- XmaI/StuI digested, dephosphorylated vector [Stratagene]. Clones were identified and oriented with respect to vector by XhoI/SstI and PvuII digests of mini-prep DNAs, respectively.

EXAMPLE 9

DNA Sequencing

DNA sequence for the CCV S gene was determined from the individual clones #1775 (AA 352-1452; SEQ ID NO:52), #2007 (AA 128-555; SEQ ID NO:43) and #2964 (AA 1-362; SEQ ID NO:53). Nested set deletions were prepared from each clone or internal primers synthesized to facilitate primer walking and the sequence determined from both strands [Lark Sequencing Technologies, Houston, Tex.]. The chain termination method performed as described in Sanger et al, Proc. Natl. Acad. Sci. USA, 74:5463-5467 (1977) was used to determine the sequence of all clones. The full length sequence of the CCV S gene was assembled from overlapping sequences of each of the three separate fragments by computer analysis.

DNA sequence analysis was performed using either Beckman Microgenie programs on an IBM Model PS12 Model 70 or the University of Wisconsin GCG package of programs implemented on a DEC VAX cluster [Devereau et al., (1984)].

SEQ ID NO:1 is the complete nucleotide sequence of the CCV strain 1-71 S gene. The amino acid [SEQ ID NO:2] and nucleotide sequences (SEQ ID NO:1 of CCV 1-71 total 1452 amino acids and 4356 base pairs. CCV 1-71 has a DNA homology of 90.8% to published FIPV strain WT WSU 1146, 93.2% identity with FIPV strain DF2 and 94.1% similarity with FECV. In comparison to WSU 1146, this CCV strain further contains two amino acid deletions at positions 11 and 12, and two amino acid insertions at positions 118 and 119. In comparison to the amino acid sequences of other coronavirus S genes, the amino acid sequence of CCV is 82.2% homologous to TGEV, 89.7% homologous to DF2-HP, 90.0% homologous to TS-BP, 92.9% homologous to TS, 93.2% homologous to DF2, and 94.1% homologous to FECV.

The canine coronavirus S gene encoding amino acids #225-1325 [SEQ ID NO:54] has an overall homology to the published WT FIPV WSU 1146 strain at amino acids 352 to 1454 of 95.9%. The homology level is increased to 97.5% when the comparison is done under the amino acid similarity rules as proposed by M. O Dayhoff, Atlas of Protein Sequence and Structure, Vol. 5, Supp. 3, Natl. Biomed. Res. Found., Washington, D.C. (1978). There are 42 amino acid differences between the CCV S gene and the published sequence of WSU 1146 strain within the CCV sequence of SEQ ID NO: 2. Other CCV fragment homologies with WT FIPV WSU 1146 are illustrated in Table II above.

Numerous modifications and variations of the present invention are included in the above-identified specification and are expected to be obvious to one of skill in the art. Such modifications and alterations to the compositions and processes of the present invention are believed to be encompassed in the scope of the claims appended hereto.

59 4359 base pairs nucleic acid double unknown DNA (genomic) CDS 1..4356 1 ATG ATT GTG
CTC GTA ACT TGC CTC TTG TTT TCG TAC AAT AGT GTG ATT 48 Met Ile Val Leu Val Thr Cys
Leu Leu Phe Ser Tyr Asn Ser Val Ile 1 5 10 15 TGT ACA TCA AAC AAT GAC TGT GTA CAA GTT
AAT GTG ACA CAA TTG CCT 96 Cys Thr Ser Asn Asn Asp Cys Val Gln Val Asn Val Thr Gln Leu
Pro 20 25 30 GGC AAT GAA AAC ATT ATT AAA GAT TTT CTA TTT CAC ACC TTC AAA GAA
144 Gly Asn Glu Asn Ile Ile Lys Asp Phe Leu Phe His Thr Phe Lys Glu 35 40 45 GAA GGA AGT
GTA GTT GTT GGT GGT TAT TAC CCT ACA GAG GTG TGG TAT 192 Glu Gly Ser Val Val Val
Gly Gly Tyr Tyr Pro Thr Glu Val Trp Tyr 50 55 60 AAC TGC TCC AGA AGC GCA ACA ACC ACC
GCT TAC AAG GAT TTT AGT AAT 240 Asn Cys Ser Arg Ser Ala Thr Thr Thr Ala Tyr Lys Asp
Phe Ser Asn 65 70 75 80 ATA CAT GCA TTC TAT TTT GAT ATG GAA GCC ATG GAG AAT AGT
ACT GGC 288 Ile His Ala Phe Tyr Phe Asp Met Glu Ala Met Glu Asn Ser Thr Gly 85 90 95 AAT

GCA CGA GGT AAA CCT TTA CTA GTA CAT GTT CAT GGT GAT CCT GTT 336 Asn Ala Arg Gly
Lys Pro Leu Leu Val His Val His Gly Asp Pro Val 100 105 110 AGT ATC ATC ATA TAT ATA TCG
GCT TAT AGA GAT GAT GTG CAA GGA AGG 384 Ser Ile Ile Ile Tyr Ile Ser Ala Tyr Arg Asp Asp
Val Gln Gly Arg 115 120 125 CCT CTT TTA AAA CAT GGT TTG TTG TGT ATA ACT AAA AAT
AAA ATC ATT 432 Pro Leu Leu Lys His Gly Leu Leu Cys Ile Thr Lys Asn Lys Ile Ile 130 135 140
GAC TAT AAC ACG TTT ACC AGC GCA CAG TGG AGT GCC ATA TGT TTG GGT 480 Asp Tyr
Asn Thr Phe Thr Ser Ala Gln Trp Ser Ala Ile Cys Leu Gly 145 150 155 160 GAT GAC AGA AAA
ATA CCA TTC TCT GTC ATA CCC ACA GGT AAT GGT ACA 528 Asp Asp Arg Lys Ile Pro Phe Ser
Val Ile Pro Thr Gly Asn Gly Thr 165 170 175 AAA ATA TTT GGT CTT GAG TGG AAT GAT GAC
TAT GTT ACA GCC TAT ATT 576 Lys Ile Phe Gly Leu Glu Trp Asn Asp Asp Tyr Val Thr Ala Tyr
Ile 180 185 190 AGT GAT CGT TCT CAC CAT TTG AAC ATC AAT AAT AAT TGG TTT AAC AAT
624 Ser Asp Arg Ser His His Leu Asn Ile Asn Asn Asn Trp Phe Asn Asn 195 200 205 GTG ACA
ATC CTA TAC TCT CGA TCA AGC ACT GCT ACG TGG CAG AAG AGT 672 Val Thr Ile Leu Tyr
Ser Arg Ser Ser Thr Ala Thr Trp Gln Lys Ser 210 215 220 GCT GCA TAT GTT TAT CAA GGT
GTT TCA AAT TTT ACT TAT TAC AAG TTA 720 Ala Ala Tyr Val Tyr Gln Gly Val Ser Asn Phe
Thr Tyr Tyr Lys Leu 225 230 235 240 AAT AAC ACC AAT GGC TTG AAA AGC TAT GAA TTG
TGT GAA GAT TAT GAA 768 Asn Asn Thr Asn Gly Leu Lys Ser Tyr Glu Leu Cys Glu Asp Tyr Glu
245 250 255 TGC TGC ACT GGC TAT GCT ACC AAC GTA TTT GCC CCG ACA GTG GGC GGT
816 Cys Cys Thr Gly Tyr Ala Thr Asn Val Phe Ala Pro Thr Val Gly Gly 260 265 270 TAT ATA
CCT GAT GGC TTC AGT TTT AAC AAT TGG TTT ATG CTT ACA AAC 864 Tyr Ile Pro Asp Gly
Phe Ser Phe Asn Asn Trp Phe Met Leu Thr Asn 275 280 285 AGT TCC ACG TTT GTT AGT GGC
AGA TTT GTA ACA AAT CAA CCA TTA TTG 912 Ser Ser Thr Phe Val Ser Gly Arg Phe Val Thr
Asn Gln Pro Leu Leu 290 295 300 GTT AAT TGT TTG TGG CCA GTG CCC AGT CTT GGT GTC
GCA GCA CAA GAA 960 Val Asn Cys Leu Trp Pro Val Pro Ser Leu Gly Val Ala Ala Gln Glu 305
310 315 320 TTT TGT TTT GAA GGT GCG CAG TTT AGC CAA TGT AAT GGT GTG TCT TTA
1008 Phe Cys Phe Glu Gly Ala Gln Phe Ser Gln Cys Asn Gly Val Ser Leu 325 330 335 AAC AAT
ACA GTG GAT GTC ATT AGA TTC AAC CTT AAT TTT ACC ACA GAT 1056 Asn Asn Thr Val Asp
Val Ile Arg Phe Asn Leu Asn Phe Thr Thr Asp 340 345 350 GTA CAA TCT GGT ATG GGT GCT
ACA GTA TTT TCA CTG AAT ACA ACA GGT 1104 Val Gln Ser Gly Met Gly Ala Thr Val Phe Ser
Leu Asn Thr Thr Gly 355 360 365 GGT GTC ATT CTT GAG ATT TCT TGT TAT AAT GAT ACA
GTG AGT GAG TCA 1152 Gly Val Ile Leu Glu Ile Ser Cys Tyr Asn Asp Thr Val Ser Glu Ser 370
375 380 AGT TTC TAC AGT TAT GGT GAA ATT TCA TTC GGC GTA ACT GAT GGA CCG 1200
Ser Phe Tyr Ser Tyr Gly Glu Ile Ser Phe Gly Val Thr Asp Gly Pro 385 390 395 400 CGT TAC TGT
TAC GCA CTC TAT AAT GGC ACG GCT CTT AAG TAT TTA GGA 1248 Arg Tyr Cys Tyr Ala Leu
Tyr Asn Gly Thr Ala Leu Lys Tyr Leu Gly 405 410 415 ACA TTA CCA CCT AGT GTC AAG GAA
ATT GCT ATT AGT AAG TGG GGC CAT 1296 Thr Leu Pro Pro Ser Val Lys Glu Ile Ala Ile Ser Lys
Trp Gly His 420 425 430 TTT TAT ATT AAT GGT TAC AAT TTC TTT AGC ACT TTT CCT ATT
GAT TGT 1344 Phe Tyr Ile Asn Gly Tyr Asn Phe Phe Ser Thr Phe Pro Ile Asp Cys 435 440 445

ATA TCT TTT AAT TTA ACC ACT GGT GAT AGT GGA GCA TTT TGG ACA ATT 1392 Ile Ser
Phe Asn Leu Thr Thr Gly Asp Ser Gly Ala Phe Trp Thr Ile 450 455 460 GCT TAC ACA TCG TAC
ACT GAC GCA TTA GTA CAA GTT GAA AAC ACA GCT 1440 Ala Tyr Thr Ser Tyr Thr Asp Ala
Leu Val Gln Val Glu Asn Thr Ala 465 470 475 480 ATT AAA AAG GTG ACG TAT TGT AAC AGT
CAC ATT AAT AAC ATT AAA TGT 1488 Ile Lys Lys Val Thr Tyr Cys Asn Ser His Ile Asn Asn Ile
Lys Cys 485 490 495 TCT CAA CTT ACT GCT AAT TTG CAA AAT GGA TTT TAT CCT GTT GCT
TCA 1536 Ser Gln Leu Thr Ala Asn Leu Gln Asn Gly Phe Tyr Pro Val Ala Ser 500 505 510 AGT
GAA GTT GGT CTT GTC AAT AAG AGT GTT GTG TTA CTA CCT AGT TTC 1584 Ser Glu Val Gly
Leu Val Asn Lys Ser Val Val Leu Leu Pro Ser Phe 515 520 525 TAT TCA CAT ACC AGT GTT AAT
ATA ACT ATT GAT CTT GGT ATG AAG CGT 1632 Tyr Ser His Thr Ser Val Asn Ile Thr Ile Asp
Leu Gly Met Lys Arg 530 535 540 AGT GGT TAT GGT CAA CCC ATA GCC TCA ACA TTA AGT
AAC ATC ACA CTA 1680 Ser Gly Tyr Gly Gln Pro Ile Ala Ser Thr Leu Ser Asn Ile Thr Leu 545
550 555 560 CCA ATG CAG GAT AAT AAC ACC GAT GTG TAC TGC ATT CGT TCT AAC CAA
1728 Pro Met Gln Asp Asn Asn Thr Asp Val Tyr Cys Ile Arg Ser Asn Gln 565 570 575 TTT TCA
GTT TAC GTT CAT TCC ACT TGT AAA AGT TCT TTA TGG GAC GAT 1776 Phe Ser Val Tyr Val
His Ser Thr Cys Lys Ser Ser Leu Trp Asp Asp 580 585 590 GTG TTT AAT TCC GAC TGC ACA
GAT GTT TTA TAT GCT ACA GCT GTT ATA 1824 Val Phe Asn Ser Asp Cys Thr Asp Val Leu Tyr
Ala Thr Ala Val Ile 595 600 605 AAA ACT GGT ACT TGT CCT TTC TCG TTT GAT AAA TTG
AAC AAT TAC TTA 1872 Lys Thr Gly Thr Cys Pro Phe Ser Phe Asp Lys Leu Asn Asn Tyr Leu 610
615 620 ACT TTT AAC AAG TTC TGT TTG TCA TTG AAT CCT GTT GGT GCC AAC TGC 1920
Thr Phe Asn Lys Phe Cys Leu Ser Leu Asn Pro Val Gly Ala Asn Cys 625 630 635 640 AAG TTT
GAT GTT GCC GCT CGT ACA AGA ACC AAT GAG CAG GTT GTT AGA 1968 Lys Phe Asp Val
Ala Ala Arg Thr Arg Thr Asn Glu Gln Val Val Arg 645 650 655 AGT TTA TAT GTA ATA TAT
GAA GAA GGA GAC AAC ATA GTG GGT GTG CCG 2016 Ser Leu Tyr Val Ile Tyr Glu Glu Gly
Asp Asn Ile Val Gly Val Pro 660 665 670 TCT GAC AAT AGT GGT CTT CAC GAC TTG TCA GTG
CTA CAC TTA GAC TCC 2064 Ser Asp Asn Ser Gly Leu His Asp Leu Ser Val Leu His Leu Asp Ser
675 680 685 TGT ACA GAT TAT AAT ATA TAT GGT AGA ACT GGT GTT GGT ATT ATT AGA
2112 Cys Thr Asp Tyr Asn Ile Tyr Gly Arg Thr Gly Val Gly Ile Ile Arg 690 695 700 CAA ACT AAC
AGT ACG CTA CTT AGT GGC TTA TAT TAC ACA TCA CTA TCA 2160 Gln Thr Asn Ser Thr Leu
Leu Ser Gly Leu Tyr Tyr Thr Ser Leu Ser 705 710 715 720 GGT GAC TTG TTA GGG TTT AAA
AAT GTT AGT GAT GGT GTC ATC TAT TCT 2208 Gly Asp Leu Leu Gly Phe Lys Asn Val Ser Asp
Gly Val Ile Tyr Ser 725 730 735 GTC ACG CCA TGT GAT GTA AGC GCA CAA GCT GCT GTT
ATT GAT GGC GCC 2256 Val Thr Pro Cys Asp Val Ser Ala Gln Ala Ala Val Ile Asp Gly Ala 740
745 750 ATA GTT GGA GCT ATG ACT TCC ATT AAT AGT GAA ATG TTA GGT CTA ACA 2304
Ile Val Gly Ala Met Thr Ser Ile Asn Ser Glu Met Leu Gly Leu Thr 755 760 765 CAT TGG ACA
ACA ACA CCT AAT TTT TAT TAT TAT TCT ATA TAT AAT TAT 2352 His Trp Thr Thr Thr Pro
Asn Phe Tyr Tyr Tyr Ser Ile Tyr Asn Tyr 770 775 780 ACC AAT GAA AGG ACT CGT GGC ACA
GCA ATT GAT AGT AAC GAT GTT GAT 2400 Thr Asn Glu Arg Thr Arg Gly Thr Ala Ile Asp Ser

Asn Asp Val Asp 785 790 795 800 TGT GAA CCT ATC ATA ACC TAT TCT AAT ATA GGT GTT
TGT AAA AAT GGA 2448 Cys Glu Pro Ile Ile Thr Tyr Ser Asn Ile Gly Val Cys Lys Asn Gly 805
810 815 GCT TTG GTT TTT ATT AAC GTC ACA CAT TCT GAT GGA GAC GTT CAA CCA 2496
Ala Leu Val Phe Ile Asn Val Thr His Ser Asp Gly Asp Val Gln Pro 820 825 830 ATT AGC ACC
GGT AAT GTC ACG ATA CCT ACA AAT TTT ACC ATA TCT GTG 2544 Ile Ser Thr Gly Asn Val
Thr Ile Pro Thr Asn Phe Thr Ile Ser Val 835 840 845 CAA GTT GAG TAC ATT CAG GTT TAC
ACT ACA CCG GTG TCA ATA GAT TGT 2592 Gln Val Glu Tyr Ile Gln Val Tyr Thr Thr Pro Val
Ser Ile Asp Cys 850 855 860 TCA AGG TAC GTT TGC AAT GGT AAC CCT AGA TGC AAT AAA
TTG TTA ACG 2640 Ser Arg Tyr Val Cys Asn Gly Asn Pro Arg Cys Asn Lys Leu Leu Thr 865 870
875 880 CAA TAC GTT TCT GCA TGT CAA ACT ATT GAG CAA GCA CTT GCA ATG GGT 2688
Gln Tyr Val Ser Ala Cys Gln Thr Ile Glu Gln Ala Leu Ala Met Gly 885 890 895 GCC AGA CTT
GAA AAC ATG GAG ATT GAT TCC ATG TTG TTT GTT TCG GAA 2736 Ala Arg Leu Glu Asn Met
Glu Ile Asp Ser Met Leu Phe Val Ser Glu 900 905 910 AAT GCC CTT AAA TTG GCA TCT GTT
GAA GCA TTC AAT AGT ACG GAA ACT 2784 Asn Ala Leu Lys Leu Ala Ser Val Glu Ala Phe Asn
Ser Thr Glu Thr 915 920 925 TTA GAT CCT ATT TAC AAA GAA TGG CCT AAC ATT GGT GGT
TCT TGG CTA 2832 Leu Asp Pro Ile Tyr Lys Glu Trp Pro Asn Ile Gly Gly Ser Trp Leu 930 935
940 GGA GGT TTA AAA GAC ATA TTG CCA TCT CAC AAC AGC AAA CGT AAG TAC 2880 Gly
Gly Leu Lys Asp Ile Leu Pro Ser His Asn Ser Lys Arg Lys Tyr 945 950 955 960 CGG TCG GCT
ATA GAA GAT TTG CTT TTT GAT AAG GTT GTA ACA TCT GGC 2928 Arg Ser Ala Ile Glu Asp
Leu Leu Phe Asp Lys Val Val Thr Ser Gly 965 970 975 TTA GGT ACA GTT GAT GAA GAT TAT
AAA CGT TGT ACA GGT GGT TAT GAC 2976 Leu Gly Thr Val Asp Glu Asp Tyr Lys Arg Cys Thr
Gly Gly Tyr Asp 980 985 990 ATA GCT GAC TTA GTG TGT GCA CAA TAT TAC AAT GGC ATC
ATG GTG CTA 3024 Ile Ala Asp Leu Val Cys Ala Gln Tyr Tyr Asn Gly Ile Met Val Leu 995 1000
1005 CCT GGT GTA GCT AAT GAT GAC AAG ATG GCT ATG TAC ACT GCA TCT CTT 3072 Pro
Gly Val Ala Asn Asp Asp Lys Met Ala Met Tyr Thr Ala Ser Leu 1010 1015 1020 GCA GGT GGT
ATA ACA TTA GGT GCA CTT GGT GGT GGC GCA GTG TCT ATA 3120 Ala Gly Gly Ile Thr Leu
Gly Ala Leu Gly Gly Gly Ala Val Ser Ile 1025 1030 1035 1040 CCT TTT GCA ATA GCA GTT CAA
GCC AGA CTT AAT TAT GTT GCT CTA CAA 3168 Pro Phe Ala Ile Ala Val Gln Ala Arg Leu Asn
Tyr Val Ala Leu Gln 1045 1050 1055 ACT GAT GTA TTG AGC AAG AAC CAG CAG ATC CTG
GCT AAT GCT TTC AAT 3216 Thr Asp Val Leu Ser Lys Asn Gln Gln Ile Leu Ala Asn Ala Phe Asn
1060 1065 1070 CAA GCT ATT GGT AAC ATT ACA CAG GCA TTT GGT AAG GTT AAT GAT
GCT 3264 Gln Ala Ile Gly Asn Ile Thr Gln Ala Phe Gly Lys Val Asn Asp Ala 1075 1080 1085 ATA
CAT CAA ACG TCA CAA GGT CTT GCT ACT GTT GCT AAA GCA TTG GCA 3312 Ile His Gln Thr
Ser Gln Gly Leu Ala Thr Val Ala Lys Ala Leu Ala 1090 1095 1100 AAA GTG CAA GAT GTT GTT
AAC ACA CAA GGG CAA GCT TTA AGC CAC CTA 3360 Lys Val Gln Asp Val Val Asn Thr Gln
Gly Gln Ala Leu Ser His Leu 1105 1110 1115 1120 ACA GTA CAA TTG CAA AAT AAT TTC CAA
GCC ATT AGT AGT TCC ATT AGT 3408 Thr Val Gln Leu Gln Asn Asn Phe Gln Ala Ile Ser Ser
Ser Ile Ser 1125 1130 1135 GAC ATT TAT AAC AGG CTT GAT GAA TTG AGT GCT GAT GCA

CAA GTT GAC 3456 Asp Ile Tyr Asn Arg Leu Asp Glu Leu Ser Ala Asp Ala Gln Val Asp 1140 1145
1150 AGG CTG ATT ACA GGA AGA CTT ACA GCA CTT AAT GCA TTT GTG TCT CAG 3504 Arg
Leu Ile Thr Gly Arg Leu Thr Ala Leu Asn Ala Phe Val Ser Gln 1155 1160 1165 ACT TTA ACC AGA
CAA GCA GAG GTT AGG GCT AGC AGA CAG CTT GCT AAA 3552 Thr Leu Thr Arg Gln Ala Glu
Val Arg Ala Ser Arg Gln Leu Ala Lys 1170 1175 1180 GAC AAG GTA AAT GAA TGC GTT AGG
TCT CAA TCT CAG AGA TTT GGA TTC 3600 Asp Lys Val Asn Glu Cys Val Arg Ser Gln Ser Gln
Arg Phe Gly Phe 1185 1190 1195 1200 TGT GGT AAT GGT ACA CAT TTA TTT TCA CTT GCA
AAT GCA GCA CCA AAT 3648 Cys Gly Asn Gly Thr His Leu Phe Ser Leu Ala Asn Ala Ala Pro
Asn 1205 1210 1215 GGC ATG ATC TTC TTT CAC ACA GTG CTA TTA CCA ACA GCT TAT GAA
ACC 3696 Gly Met Ile Phe Phe His Thr Val Leu Leu Pro Thr Ala Tyr Glu Thr 1220 1225 1230
GTG ACG GCC TGG TCA GGT ATT TGT GCA TCA GAT GGC GAT CGT ACT TTT 3744 Val Thr
Ala Trp Ser Gly Ile Cys Ala Ser Asp Gly Asp Arg Thr Phe 1235 1240 1245 GGA CTT GTT GTT
AAG GAT GTC CAG TTG ACG CTG TTT CGC AAT CTA GAT 3792 Gly Leu Val Val Lys Asp Val
Gln Leu Thr Leu Phe Arg Asn Leu Asp 1250 1255 1260 GAC AAA TTC TAT TTG ACT CCC AGA
ACT ATG TAT CAG CCT AGA GTT GCA 3840 Asp Lys Phe Tyr Leu Thr Pro Arg Thr Met Tyr Gln
Pro Arg Val Ala 1265 1270 1275 1280 ACT AGT TCT GAT TTT GTT CAA ATT GAA GGA TGT
GAT GTG TTG TTT GTT 3888 Thr Ser Ser Asp Phe Val Gln Ile Glu Gly Cys Asp Val Leu Phe Val
1285 1290 1295 AAT GCA ACT GTA ATT GAC TTG CCT AGT ATT ATA CCT GAC TAT ATT GAT
3936 Asn Ala Thr Val Ile Asp Leu Pro Ser Ile Ile Pro Asp Tyr Ile Asp 1300 1305 1310 ATT AAT
CAA ACT GTT CAG GAC ATA TTA GAA AAT TTC AGA CCA AAT TGG 3984 Ile Asn Gln Thr Val
Gln Asp Ile Leu Glu Asn Phe Arg Pro Asn Trp 1315 1320 1325 ACT GTA CCT GAG TTG CCA CTT
GAC ATT TTC AAT GCA ACC TAC TTA AAC 4032 Thr Val Pro Glu Leu Pro Leu Asp Ile Phe Asn
Ala Thr Tyr Leu Asn 1330 1335 1340 CTG ACT GGT GAA ATT AAT GAC TTA GAA TTT AGG
TCA GAA AAG TTA CAT 4080 Leu Thr Gly Glu Ile Asn Asp Leu Glu Phe Arg Ser Glu Lys Leu
His 1345 1350 1355 1360 AAC ACC ACA GTA GAA CTT GCT ATT CTC ATT GAT AAT ATT AAT
AAC ACA 4128 Asn Thr Thr Val Glu Leu Ala Ile Leu Ile Asp Asn Ile Asn Asn Thr 1365 1370 1375
TTA GTC AAT CTT GAA TGG CTC AAT AGA ATT GAA ACT TAT GTA AAA TGG 4176 Leu Val
Asn Leu Glu Trp Leu Asn Arg Ile Glu Thr Tyr Val Lys Trp 1380 1385 1390 CCT TGG TAT GTG
TGG CTA CTA ATT GGA TTA GTA GTA ATA TTC TGC ATA 4224 Pro Trp Tyr Val Trp Leu Leu
Ile Gly Leu Val Val Ile Phe Cys Ile 1395 1400 1405 CCC ATA TTG CTA TTT TGT TGT TGT AGC
ACT GGT TGT TGT GGA TGT ATT 4272 Pro Ile Leu Leu Phe Cys Cys Cys Ser Thr Gly Cys Cys
Gly Cys Ile 1410 1415 1420 GGG TGT TTA GGA AGC TGT TGT CAT TCC ATA TGT AGT AGA
AGG CGA TTT 4320 Gly Cys Leu Gly Ser Cys Cys His Ser Ile Cys Ser Arg Arg Arg Phe 1425 1430
1435 1440 GAA AGT TAT GAA CCA ATT GAA AAA GTG CAT GTC CAC TAA 4359 Glu Ser Tyr
Glu Pro Ile Glu Lys Val His Val His 1445 1450 1452 amino acids amino acid linear protein 2 Met
Ile Val Leu Val Thr Cys Leu Leu Phe Ser Tyr Asn Ser Val Ile 1 5 10 15 Cys Thr Ser Asn Asn Asp
Cys Val Gln Val Asn Val Thr Gln Leu Pro 20 25 30 Gly Asn Glu Asn Ile Ile Lys Asp Phe Leu Phe
His Thr Phe Lys Glu 35 40 45 Glu Gly Ser Val Val Val Gly Gly Tyr Tyr Pro Thr Glu Val Trp Tyr

50 55 60 Asn Cys Ser Arg Ser Ala Thr Thr Thr Ala Tyr Lys Asp Phe Ser Asn 65 70 75 80 Ile His
Ala Phe Tyr Phe Asp Met Glu Ala Met Glu Asn Ser Thr Gly 85 90 95 Asn Ala Arg Gly Lys Pro Leu
Leu Val His Val His Gly Asp Pro Val 100 105 110 Ser Ile Ile Ile Tyr Ile Ser Ala Tyr Arg Asp Asp
Val Gln Gly Arg 115 120 125 Pro Leu Leu Lys His Gly Leu Leu Cys Ile Thr Lys Asn Lys Ile Ile 130
135 140 Asp Tyr Asn Thr Phe Thr Ser Ala Gln Trp Ser Ala Ile Cys Leu Gly 145 150 155 160 Asp
Asp Arg Lys Ile Pro Phe Ser Val Ile Pro Thr Gly Asn Gly Thr 165 170 175 Lys Ile Phe Gly Leu Glu
Trp Asn Asp Asp Tyr Val Thr Ala Tyr Ile 180 185 190 Ser Asp Arg Ser His His Leu Asn Ile Asn
Asn Asn Trp Phe Asn Asn 195 200 205 Val Thr Ile Leu Tyr Ser Arg Ser Ser Thr Ala Thr Trp Gln
Lys Ser 210 215 220 Ala Ala Tyr Val Tyr Gln Gly Val Ser Asn Phe Thr Tyr Tyr Lys Leu 225 230
235 240 Asn Asn Thr Asn Gly Leu Lys Ser Tyr Glu Leu Cys Glu Asp Tyr Glu 245 250 255 Cys Cys
Thr Gly Tyr Ala Thr Asn Val Phe Ala Pro Thr Val Gly Gly 260 265 270 Tyr Ile Pro Asp Gly Phe
Ser Phe Asn Asn Trp Phe Met Leu Thr Asn 275 280 285 Ser Ser Thr Phe Val Ser Gly Arg Phe Val
Thr Asn Gln Pro Leu Leu 290 295 300 Val Asn Cys Leu Trp Pro Val Pro Ser Leu Gly Val Ala Ala
Gln Glu 305 310 315 320 Phe Cys Phe Glu Gly Ala Gln Phe Ser Gln Cys Asn Gly Val Ser Leu 325
330 335 Asn Asn Thr Val Asp Val Ile Arg Phe Asn Leu Asn Phe Thr Thr Asp 340 345 350 Val Gln
Ser Gly Met Gly Ala Thr Val Phe Ser Leu Asn Thr Thr Gly 355 360 365 Gly Val Ile Leu Glu Ile
Ser Cys Tyr Asn Asp Thr Val Ser Glu Ser 370 375 380 Ser Phe Tyr Ser Tyr Gly Glu Ile Ser Phe
Gly Val Thr Asp Gly Pro 385 390 395 400 Arg Tyr Cys Tyr Ala Leu Tyr Asn Gly Thr Ala Leu Lys
Tyr Leu Gly 405 410 415 Thr Leu Pro Pro Ser Val Lys Glu Ile Ala Ile Ser Lys Trp Gly His 420 425
430 Phe Tyr Ile Asn Gly Tyr Asn Phe Phe Ser Thr Phe Pro Ile Asp Cys 435 440 445 Ile Ser Phe
Asn Leu Thr Thr Gly Asp Ser Gly Ala Phe Trp Thr Ile 450 455 460 Ala Tyr Thr Ser Tyr Thr Asp
Ala Leu Val Gln Val Glu Asn Thr Ala 465 470 475 480 Ile Lys Lys Val Thr Tyr Cys Asn Ser His
Ile Asn Asn Ile Lys Cys 485 490 495 Ser Gln Leu Thr Ala Asn Leu Gln Asn Gly Phe Tyr Pro Val
Ala Ser 500 505 510 Ser Glu Val Gly Leu Val Asn Lys Ser Val Val Leu Leu Pro Ser Phe 515 520
525 Tyr Ser His Thr Ser Val Asn Ile Thr Ile Asp Leu Gly Met Lys Arg 530 535 540 Ser Gly Tyr
Gly Gln Pro Ile Ala Ser Thr Leu Ser Asn Ile Thr Leu 545 550 555 560 Pro Met Gln Asp Asn Asn
Thr Asp Val Tyr Cys Ile Arg Ser Asn Gln 565 570 575 Phe Ser Val Tyr Val His Ser Thr Cys Lys Ser
Ser Leu Trp Asp Asp 580 585 590 Val Phe Asn Ser Asp Cys Thr Asp Val Leu Tyr Ala Thr Ala Val
Ile 595 600 605 Lys Thr Gly Thr Cys Pro Phe Ser Phe Asp Lys Leu Asn Asn Tyr Leu 610 615 620
Thr Phe Asn Lys Phe Cys Leu Ser Leu Asn Pro Val Gly Ala Asn Cys 625 630 635 640 Lys Phe Asp
Val Ala Ala Arg Thr Arg Thr Asn Glu Gln Val Val Arg 645 650 655 Ser Leu Tyr Val Ile Tyr Glu
Glu Gly Asp Asn Ile Val Gly Val Pro 660 665 670 Ser Asp Asn Ser Gly Leu His Asp Leu Ser Val
Leu His Leu Asp Ser 675 680 685 Cys Thr Asp Tyr Asn Ile Tyr Gly Arg Thr Gly Val Gly Ile Ile Arg
690 695 700 Gln Thr Asn Ser Thr Leu Leu Ser Gly Leu Tyr Tyr Thr Ser Leu Ser 705 710 715 720
Gly Asp Leu Leu Gly Phe Lys Asn Val Ser Asp Gly Val Ile Tyr Ser 725 730 735 Val Thr Pro Cys
Asp Val Ser Ala Gln Ala Ala Val Ile Asp Gly Ala 740 745 750 Ile Val Gly Ala Met Thr Ser Ile Asn
Ser Glu Met Leu Gly Leu Thr 755 760 765 His Trp Thr Thr Thr Pro Asn Phe Tyr Tyr Tyr Ser Ile
Tyr Asn Tyr 770 775 780 Thr Asn Glu Arg Thr Arg Gly Thr Ala Ile Asp Ser Asn Asp Val Asp 785

790 795 800 Cys Glu Pro Ile Ile Thr Tyr Ser Asn Ile Gly Val Cys Lys Asn Gly 805 810 815 Ala Leu
Val Phe Ile Asn Val Thr His Ser Asp Gly Asp Val Gln Pro 820 825 830 Ile Ser Thr Gly Asn Val
Thr Ile Pro Thr Asn Phe Thr Ile Ser Val 835 840 845 Gln Val Glu Tyr Ile Gln Val Tyr Thr Thr Pro
Val Ser Ile Asp Cys 850 855 860 Ser Arg Tyr Val Cys Asn Gly Asn Pro Arg Cys Asn Lys Leu Leu
Thr 865 870 875 880 Gln Tyr Val Ser Ala Cys Gln Thr Ile Glu Gln Ala Leu Ala Met Gly 885 890
895 Ala Arg Leu Glu Asn Met Glu Ile Asp Ser Met Leu Phe Val Ser Glu 900 905 910 Asn Ala Leu
Lys Leu Ala Ser Val Glu Ala Phe Asn Ser Thr Glu Thr 915 920 925 Leu Asp Pro Ile Tyr Lys Glu
Trp Pro Asn Ile Gly Gly Ser Trp Leu 930 935 940 Gly Gly Leu Lys Asp Ile Leu Pro Ser His Asn
Ser Lys Arg Lys Tyr 945 950 955 960 Arg Ser Ala Ile Glu Asp Leu Leu Phe Asp Lys Val Val Thr
Ser Gly 965 970 975 Leu Gly Thr Val Asp Glu Asp Tyr Lys Arg Cys Thr Gly Gly Tyr Asp 980 985
990 Ile Ala Asp Leu Val Cys Ala Gln Tyr Tyr Asn Gly Ile Met Val Leu 995 1000 1005 Pro Gly Val
Ala Asn Asp Asp Lys Met Ala Met Tyr Thr Ala Ser Leu 1010 1015 1020 Ala Gly Gly Ile Thr Leu
Gly Ala Leu Gly Gly Gly Ala Val Ser Ile 1025 1030 1035 1040 Pro Phe Ala Ile Ala Val Gln Ala Arg
Leu Asn Tyr Val Ala Leu Gln 1045 1050 1055 Thr Asp Val Leu Ser Lys Asn Gln Gln Ile Leu Ala
Asn Ala Phe Asn 1060 1065 1070 Gln Ala Ile Gly Asn Ile Thr Gln Ala Phe Gly Lys Val Asn Asp
Ala 1075 1080 1085 Ile His Gln Thr Ser Gln Gly Leu Ala Thr Val Ala Lys Ala Leu Ala 1090 1095
1100 Lys Val Gln Asp Val Val Asn Thr Gln Gly Gln Ala Leu Ser His Leu 1105 1110 1115 1120 Thr
Val Gln Leu Gln Asn Asn Phe Gln Ala Ile Ser Ser Ser Ile Ser 1125 1130 1135 Asp Ile Tyr Asn Arg
Leu Asp Glu Leu Ser Ala Asp Ala Gln Val Asp 1140 1145 1150 Arg Leu Ile Thr Gly Arg Leu Thr
Ala Leu Asn Ala Phe Val Ser Gln 1155 1160 1165 Thr Leu Thr Arg Gln Ala Glu Val Arg Ala Ser Arg
Gln Leu Ala Lys 1170 1175 1180 Asp Lys Val Asn Glu Cys Val Arg Ser Gln Ser Gln Arg Phe Gly
Phe 1185 1190 1195 1200 Cys Gly Asn Gly Thr His Leu Phe Ser Leu Ala Asn Ala Ala Pro Asn 1205
1210 1215 Gly Met Ile Phe Phe His Thr Val Leu Leu Pro Thr Ala Tyr Glu Thr 1220 1225 1230 Val
Thr Ala Trp Ser Gly Ile Cys Ala Ser Asp Gly Asp Arg Thr Phe 1235 1240 1245 Gly Leu Val Val Lys
Asp Val Gln Leu Thr Leu Phe Arg Asn Leu Asp 1250 1255 1260 Asp Lys Phe Tyr Leu Thr Pro Arg
Thr Met Tyr Gln Pro Arg Val Ala 1265 1270 1275 1280 Thr Ser Ser Asp Phe Val Gln Ile Glu Gly
Cys Asp Val Leu Phe Val 1285 1290 1295 Asn Ala Thr Val Ile Asp Leu Pro Ser Ile Ile Pro Asp Tyr
Ile Asp 1300 1305 1310 Ile Asn Gln Thr Val Gln Asp Ile Leu Glu Asn Phe Arg Pro Asn Trp 1315
1320 1325 Thr Val Pro Glu Leu Pro Leu Asp Ile Phe Asn Ala Thr Tyr Leu Asn 1330 1335 1340
Leu Thr Gly Glu Ile Asn Asp Leu Glu Phe Arg Ser Glu Lys Leu His 1345 1350 1355 1360 Asn Thr
Thr Val Glu Leu Ala Ile Leu Ile Asp Asn Ile Asn Asn Thr 1365 1370 1375 Leu Val Asn Leu Glu Trp
Leu Asn Arg Ile Glu Thr Tyr Val Lys Trp 1380 1385 1390 Pro Trp Tyr Val Trp Leu Leu Ile Gly
Leu Val Val Ile Phe Cys Ile 1395 1400 1405 Pro Ile Leu Leu Phe Cys Cys Cys Ser Thr Gly Cys Cys
Gly Cys Ile 1410 1415 1420 Gly Cys Leu Gly Ser Cys Cys His Ser Ile Cys Ser Arg Arg Arg Phe 1425
1430 1435 1440 Glu Ser Tyr Glu Pro Ile Glu Lys Val His Val His 1445 1450 201 amino acids
amino acid unknown protein 3 Gly Ser Val Val Val Gly Gly Tyr Tyr Pro Thr Glu Val Trp Tyr As 1
5 10 15 Cys Ser Arg Ser Ala Thr Thr Thr Ala Tyr Lys Asp Phe Ser Asn Il 20 25 30 His Ala Phe Tyr
Phe Asp Met Glu Ala Met Glu Asn Ser Thr Gly As 35 40 45 Ala Arg Gly Lys Pro Leu Leu Val His

Val His Gly Asp Pro Val Se 50 55 60 Ile Ile Ile Tyr Ile Ser Ala Tyr Arg Asp Asp Val Gln Gly Arg Pr
65 70 75 80 Leu Leu Lys His Gly Leu Leu Cys Ile Thr Lys Asn Lys Ile Ile As 85 90 95 Tyr Asn Thr
Phe Thr Ser Ala Gln Trp Ser Ala Ile Cys Leu Gly As 100 105 110 Asp Arg Lys Ile Pro Phe Ser Val
Ile Pro Thr Gly Asn Gly Thr Ly 115 120 125 Ile Phe Gly Leu Glu Trp Asn Asp Asp Tyr Val Thr Ala
Tyr Ile Se 130 135 140 Asp Arg Ser His His Leu Asn Ile Asn Asn Asn Trp Phe Asn Asn Va 145 150
155 160 Thr Ile Leu Tyr Ser Arg Ser Ser Thr Ala Thr Trp Gln Lys Ser Al 165 170 175 Ala Tyr Val
Tyr Gln Gly Val Ser Asn Phe Thr Tyr Tyr Lys Leu As 180 185 190 Asn Thr Asn Gly Leu Lys Ser
Tyr Glu 195 200 51 amino acids amino acid unknown protein 4 Ser Cys Tyr Asn Asp Thr Val Ser
Glu Ser Ser Phe Tyr Ser Tyr Gl 1 5 10 15 Glu Ile Ser Phe Gly Val Thr Asp Gly Pro Arg Tyr Cys Tyr
Ala Le 20 25 30 Tyr Asn Gly Thr Ala Leu Lys Tyr Leu Gly Thr Leu Pro Pro Ser Va 35 40 45 Lys
Glu Ile 50 21 amino acids amino acid unknown protein 5 Ser Phe Asn Leu Thr Thr Gly Asp Ser
Gly Ala Phe Trp Thr Ile Al 1 5 10 15 Tyr Thr Ser Tyr Thr 20 51 amino acids amino acid unknown
protein 6 Pro Ile Ala Ser Thr Leu Ser Asn Ile Thr Leu Pro Met Gln Asp As 1 5 10 15 Asn Thr Asp
Val Tyr Cys Ile Arg Ser Asn Gln Phe Ser Val Tyr Va 20 25 30 His Ser Thr Cys Lys Ser Ser Leu Trp
Asp Asp Val Phe Asn Ser As 35 40 45 Cys Thr Asp 50 51 amino acids amino acid unknown
protein 7 Thr Asn Glu Gln Val Val Arg Ser Leu Tyr Val Ile Tyr Glu Glu Gl 1 5 10 15 Asp Asn Ile
Val Gly Val Pro Ser Asp Asn Ser Gly Leu His Asp Le 20 25 30 Ser Val Leu His Leu Asp Ser Cys
Thr Asp Tyr Asn Ile Tyr Gly Ar 35 40 45 Thr Gly Val 50 81 amino acids amino acid unknown
protein 8 Trp Thr Thr Thr Pro Asn Phe Tyr Tyr Tyr Ser Ile Tyr Asn Tyr Th 1 5 10 15 Asn Glu Arg
Thr Arg Gly Thr Ala Ile Asp Ser Asn Asp Val Asp Cy 20 25 30 Glu Pro Ile Ile Thr Tyr Ser Asn Ile
Gly Val Cys Lys Asn Gly Al 35 40 45 Leu Val Phe Ile Asn Val Thr His Ser Asp Gly Asp Val Gln
Pro Il 50 55 60 Ser Thr Gly Asn Val Thr Ile Pro Thr Asn Phe Thr Ile Ser Val Gl 65 70 75 80 Val
126 amino acids amino acid unknown protein 9 Glu Asn Met Glu Ile Asp Ser Met Leu Phe Val
Ser Glu Asn Ala Le 1 5 10 15 Lys Leu Ala Ser Val Glu Ala Phe Asn Ser Thr Glu Thr Leu Asp Pr 20
25 30 Ile Tyr Lys Glu Trp Pro Asn Ile Gly Gly Ser Trp Leu Gly Gly Le 35 40 45 Lys Asp Ile Leu
Pro Ser His Asn Ser Lys Arg Lys Tyr Arg Ser Al 50 55 60 Ile Glu Asp Leu Leu Phe Asp Lys Val
Val Thr Ser Gly Leu Gly Th 65 70 75 80 Val Asp Glu Asp Tyr Lys Arg Cys Thr Gly Gly Tyr Asp Ile
Ala As 85 90 95 Leu Val Cys Ala Gln Tyr Tyr Asn Gly Ile Met Val Leu Pro Gly Va 100 105 110 Ala
Asn Asp Asp Lys Met Ala Met Tyr Thr Ala Ser Leu Ala 115 120 125 76 amino acids amino acid
unknown protein 10 Gln Val Asp Arg Leu Ile Thr Gly Arg Leu Thr Ala Leu Asn Ala Ph 1 5 10 15
Val Ser Gln Thr Leu Thr Arg Gln Ala Glu Val Arg Ala Ser Arg Gl 20 25 30 Leu Ala Lys Asp Lys
Val Asn Glu Cys Val Arg Ser Gln Ser Gln Ar 35 40 45 Phe Gly Phe Cys Gly Asn Gly Thr His Leu
Phe Ser Leu Ala Asn Al 50 55 60 Ala Pro Asn Gly Met Ile Phe Phe His Thr Val Leu 65 70 75 203
amino acids amino acid unknown protein 11 Leu Val Val Lys Asp Val Gln Leu Thr Leu Phe Arg
Asn Leu Asp As 1 5 10 15 Lys Phe Tyr Leu Thr Pro Arg Thr Met Tyr Gln Pro Arg Val Ala Th 20 25
30 Ser Ser Asp Phe Val Gln Ile Glu Gly Cys Asp Val Leu Phe Val As 35 40 45 Ala Thr Val Ile Asp
Leu Pro Ser Ile Ile Pro Asp Tyr Ile Asp Il 50 55 60 Asn Gln Thr Val Gln Asp Ile Leu Glu Asn Phe
Arg Pro Asn Trp Th 65 70 75 80 Val Pro Glu Leu Pro Leu Asp Ile Phe Asn Ala Thr Tyr Leu Asn

Le 85 90 95 Thr Gly Glu Ile Asn Asp Leu Glu Phe Arg Ser Glu Lys Leu His As 100 105 110 Thr
Thr Val Glu Leu Ala Ile Leu Ile Asp Asn Ile Asn Asn Thr Le 115 120 125 Val Asn Leu Glu Trp Leu
Asn Arg Ile Glu Thr Tyr Val Lys Trp Pr 130 135 140 Trp Tyr Val Trp Leu Leu Ile Gly Leu Val Val
Ile Phe Cys Ile Pr 145 150 155 160 Ile Leu Leu Phe Cys Cys Cys Ser Thr Gly Cys Cys Gly Cys Ile Gl
165 170 175 Cys Leu Gly Ser Cys Cys His Ser Ile Cys Ser Arg Arg Arg Phe Gl 180 185 190 Ser Tyr
Glu Pro Ile Glu Lys Val His Val His 195 200 8 amino acids amino acid unknown protein 12 Asp
Phe Leu Phe His Thr Phe Lys 1 5 19 amino acids amino acid unknown protein 13 Trp Tyr Asn
Cys Ser Arg Ser Ala Thr Thr Thr Ala Tyr Lys Asp Phe 1 5 10 15 Ser Asn Ile 5 amino acids amino
acid unknown protein 14 Tyr Val Thr Ala Tyr 1 5 34 amino acids amino acid unknown protein 15
Asn Asn Thr Asn Gly Leu Lys Ser Tyr Glu Leu Cys Glu Asp Tyr Glu 1 5 10 15 Cys Cys Thr Gly Tyr
Ala Thr Asn Val Phe Ala Pro Thr Val Gly Gly 20 25 30 Tyr Ile 7 amino acids amino acid
unknown protein 16 Ser Leu Asn Asn Thr Val Asp 1 5 34 amino acids amino acid unknown
protein 17 Gly Val Thr Asp Gly Pro Arg Tyr Cys Tyr Ala Leu Tyr Asn Gly Thr 1 5 10 15 Ala Leu
Lys Tyr Leu Gly Thr Leu Pro Pro Ser Val Lys Glu Ile Ala 20 25 30 Ile Ser 27 amino acids amino
acid unknown protein 18 Ser Tyr Thr Asp Ala Leu Val Gln Val Glu Asn Thr Ala Ile Lys Lys 1 5 10
15 Val Thr Tyr Cys Asn Ser His Ile Asn Asn Ile 20 25 15 amino acids amino acid unknown
protein 19 Ile Ser Val Gln Val Glu Tyr Ile Gln Val Tyr Thr Thr Pro Val 1 5 10 15 37 amino acids
amino acid unknown protein 20 Lys Leu Ala Ser Val Glu Ala Phe Asn Ser Thr Glu Thr Leu Asp
Pro 1 5 10 15 Ile Tyr Lys Glu Trp Pro Asn Ile Gly Gly Ser Trp Leu Gly Gly Leu 20 25 30 Lys Asp
Ile Leu Pro 35 16 amino acids amino acid unknown protein 21 Leu Gly Thr Val Asp Glu Asp Tyr
Lys Arg Cys Thr Gly Gly Tyr Asp 1 5 10 15 78 amino acids amino acid unknown protein 22 Ala
Asn Ala Phe Asn Gln Ala Ile Gly Asn Ile Thr Gln Ala Phe Gly 1 5 10 15 Lys Val Asn Asp Ala Ile
His Gln Thr Ser Gln Gly Leu Ala Thr Val 20 25 30 Ala Lys Ala Leu Ala Lys Val Gln Asp Val Val
Asn Thr Gln Gly Gln 35 40 45 Ala Leu Ser His Leu Thr Val Gln Leu Gln Asn Asn Phe Gln Ala Ile
50 55 60 Ser Ser Ser Ile Ser Asp Ile Tyr Asn Arg Leu Asp Glu Leu 65 70 75 26 amino acids amino
acid unknown protein 23 Leu Ala Ile Leu Ile Asp Asn Ile Asn Asn Thr Leu Val Asn Leu Glu 1 5 10
15 Trp Leu Asn Arg Ile Glu Thr Tyr Val Lys 20 25 372 base pairs nucleic acid double unknown
DNA (genomic) CDS 1..372 24 CAA GGG CAA GCT TTA AGC CAC CTA ACA GTA CAA TTG CAA
AAT AAT TTC 48 Gln Gly Gln Ala Leu Ser His Leu Thr Val Gln Leu Gln Asn Asn Phe 1 5 10 15
CAA GCC ATT AGT AGT TCC ATT AGT GAC ATT TAT AAC AGG CTT GAT GAA 96 Gln Ala Ile
Ser Ser Ser Ile Ser Asp Ile Tyr Asn Arg Leu Asp Glu 20 25 30 TTG AGT GCT GAT GCA CAA GTT
GAC AGG CTG ATT ACA GGA AGA CTT ACA 144 Leu Ser Ala Asp Ala Gln Val Asp Arg Leu Ile
Thr Gly Arg Leu Thr 35 40 45 GCA CTT AAT GCA TTT GTG TCT CAG ACT TTA ACC AGA CAA
GCA GAG GTT 192 Ala Leu Asn Ala Phe Val Ser Gln Thr Leu Thr Arg Gln Ala Glu Val 50 55 60
AGG GCT AGC AGA CAG CTT GCT AAA GAC AAG GTA AAT GAA TGC GTT AGG 240 Arg Ala
Ser Arg Gln Leu Ala Lys Asp Lys Val Asn Glu Cys Val Arg 65 70 75 80 TCT CAA TCT CAG AGA
TTT GGA TTC TGT GGT AAT GGT ACA CAT TTA TTT 288 Ser Gln Ser Gln Arg Phe Gly Phe Cys
Gly Asn Gly Thr His Leu Phe 85 90 95 TCA CTT GCA AAT GCA GCA CCA AAT GGC ATG ATC

TTC TTT CAC ACA GTG 336 Ser Leu Ala Asn Ala Ala Pro Asn Gly Met Ile Phe Phe His Thr Val
100 105 110 CTA TTA CCA ACA GCT TAT GAA ACC GTG ACG GCC TGG 372 Leu Leu Pro Thr
Ala Tyr Glu Thr Val Thr Ala Trp 115 120 124 amino acids amino acid linear protein 25 Gln Gly
Gln Ala Leu Ser His Leu Thr Val Gln Leu Gln Asn Asn Phe 1 5 10 15 Gln Ala Ile Ser Ser Ser Ile
Ser Asp Ile Tyr Asn Arg Leu Asp Glu 20 25 30 Leu Ser Ala Asp Ala Gln Val Asp Arg Leu Ile Thr
Gly Arg Leu Thr 35 40 45 Ala Leu Asn Ala Phe Val Ser Gln Thr Leu Thr Arg Gln Ala Glu Val 50
55 60 Arg Ala Ser Arg Gln Leu Ala Lys Asp Lys Val Asn Glu Cys Val Arg 65 70 75 80 Ser Gln Ser
Gln Arg Phe Gly Phe Cys Gly Asn Gly Thr His Leu Phe 85 90 95 Ser Leu Ala Asn Ala Ala Pro Asn
Gly Met Ile Phe Phe His Thr Val 100 105 110 Leu Leu Pro Thr Ala Tyr Glu Thr Val Thr Ala Trp
115 120 180 base pairs nucleic acid double unknown DNA (genomic) CDS 1..180 26 CTT GGT
ATG AAG CGT AGT GGT TAT GGT CAA CCC ATA GCC TCA ACA TTA 48 Leu Gly Met Lys Arg
Ser Gly Tyr Gly Gln Pro Ile Ala Ser Thr Leu 1 5 10 15 AGT AAC ATC ACA CTA CCA ATG CAG
GAT AAT AAC ACC GAT GTG TAC TGC 96 Ser Asn Ile Thr Leu Pro Met Gln Asp Asn Asn Thr
Asp Val Tyr Cys 20 25 30 ATT CGT TCT AAC CAA TTT TCA GTT TAC GTT CAT TCC ACT TGT
AAA AGT 144 Ile Arg Ser Asn Gln Phe Ser Val Tyr Val His Ser Thr Cys Lys Ser 35 40 45 TCT
TTA TGG GAC GAT GTG TTT AAT TCC GAC TGC ACA 180 Ser Leu Trp Asp Asp Val Phe Asn
Ser Asp Cys Thr 50 55 60 60 amino acids amino acid linear protein 27 Leu Gly Met Lys Arg Ser
Gly Tyr Gly Gln Pro Ile Ala Ser Thr Leu 1 5 10 15 Ser Asn Ile Thr Leu Pro Met Gln Asp Asn Asn
Thr Asp Val Tyr Cys 20 25 30 Ile Arg Ser Asn Gln Phe Ser Val Tyr Val His Ser Thr Cys Lys Ser 35
40 45 Ser Leu Trp Asp Asp Val Phe Asn Ser Asp Cys Thr 50 55 60 141 base pairs nucleic acid
double unknown DNA (genomic) CDS 1..141 28 GTC ATT AGA TTC AAC CTT AAT TTT ACC
ACA GAT GTA CAA TCT GGT ATG 48 Val Ile Arg Phe Asn Leu Asn Phe Thr Thr Asp Val Gln Ser
Gly Met 1 5 10 15 GGT GCT ACA GTA TTT TCA CTG AAT ACA ACA GGT GGT GTC ATT CTT
GAG 96 Gly Ala Thr Val Phe Ser Leu Asn Thr Thr Gly Gly Val Ile Leu Glu 20 25 30 ATT TCT
TGT TAT AAT GAT ACA GTG AGT GAG TCA AGT TTC TAC AGT 141 Ile Ser Cys Tyr Asn Asp
Thr Val Ser Glu Ser Ser Phe Tyr Ser 35 40 45 47 amino acids amino acid linear protein 29 Val Ile
Arg Phe Asn Leu Asn Phe Thr Thr Asp Val Gln Ser Gly Met 1 5 10 15 Gly Ala Thr Val Phe Ser Leu
Asn Thr Thr Gly Gly Val Ile Leu Glu 20 25 30 Ile Ser Cys Tyr Asn Asp Thr Val Ser Glu Ser Ser
Phe Tyr Ser 35 40 45 51 base pairs nucleic acid double unknown DNA (genomic) CDS 1..51 30
TGT ATA ACT AAA AAT AAA ATC ATT GAC TAT AAC ACG TTT ACC AGC GCA 48 Cys Ile Thr
Lys Asn Lys Ile Ile Asp Tyr Asn Thr Phe Thr Ser Ala 1 5 10 15 CAG 51 Gln 17 amino acids amino
acid linear protein 31 Cys Ile Thr Lys Asn Lys Ile Ile Asp Tyr Asn Thr Phe Thr Ser Ala 1 5 10 15
Gln 42 base pairs nucleic acid double unknown DNA (genomic) CDS 1..42 32 TCT TGT TAT
AAT GAT ACA GTG AGT GAG TCA AGT TTC TAC AGT 42 Ser Cys Tyr Asn Asp Thr Val Ser Glu
Ser Ser Phe Tyr Ser 1 5 10 14 amino acids amino acid linear protein 33 Ser Cys Tyr Asn Asp Thr
Val Ser Glu Ser Ser Phe Tyr Ser 1 5 10 51 base pairs nucleic acid double unknown DNA
(genomic) CDS 1..51 34 ATT GGG TGT TTA GGA AGC TGT TGT CAT TCC ATA TGT AGT AGA
AGG CGA 48 Ile Gly Cys Leu Gly Ser Cys Cys His Ser Ile Cys Ser Arg Arg Arg 1 5 10 15 TTT 51

Phe 17 amino acids amino acid linear protein 35 Ile Gly Cys Leu Gly Ser Cys Cys His Ser Ile Cys Ser Arg Arg Arg 1 5 10 15 Phe 42 base pairs nucleic acid double unknown DNA (genomic) CDS 1..42 36 TGC ATA CCC ATA TTG CTA TTT TGT TGT TGT AGC ACT GGT TGT 42 Cys Ile Pro Ile Leu Leu Phe Cys Cys Cys Ser Thr Gly Cys 1 5 10 14 amino acids amino acid linear protein 37 Cys Ile Pro Ile Leu Leu Phe Cys Cys Cys Ser Thr Gly Cys 1 5 10 195 base pairs nucleic acid double unknown DNA (genomic) CDS 1..195 38 TAC TTA AAC CTG ACT GGT GAA ATT AAT GAC TTA GAA TTT AGG TCA GAA 48 Tyr Leu Asn Leu Thr Gly Glu Ile Asn Asp Leu Glu Phe Arg Ser Glu 1 5 10 15 AAG TTA CAT AAC ACC ACA GTA GAA CTT GCT ATT CTC ATT GAT AAT ATT 96 Lys Leu His Asn Thr Thr Val Glu Leu Ala Ile Leu Ile Asp Asn Ile 20 25 30 AAT AAC ACA TTA GTC AAT CTT GAA TGG CTC AAT AGA ATT GAA ACT TAT 144 Asn Asn Thr Leu Val Asn Leu Glu Trp Leu Asn Arg Ile Glu Thr Tyr 35 40 45 GTA AAA TGG CCT TGG TAT GTG TGG CTA CTA ATT GGA TTA GTA GTA ATA 192 Val Lys Trp Pro Trp Tyr Val Trp Leu Leu Ile Gly Leu Val Val Ile 50 55 60 TTC 195 Phe 65 65 amino acids amino acid linear protein 39 Tyr Leu Asn Leu Thr Gly Glu Ile Asn Asp Leu Glu Phe Arg Ser Glu 1 5 10 15 Lys Leu His Asn Thr Thr Val Glu Leu Ala Ile Leu Ile Asp Asn Ile 20 25 30 Asn Asn Thr Leu Val Asn Leu Glu Trp Leu Asn Arg Ile Glu Thr Tyr 35 40 45 Val Lys Trp Pro Trp Tyr Val Trp Leu Leu Ile Gly Leu Val Val Ile 50 55 60 Phe 65 765 base pairs nucleic acid double unknown DNA (genomic) CDS 1..765 40 GAT GGA CCG CGT TAC TGT TAC GCA CTC TAT AAT GGC ACG GCT CTT AAG 48 Asp Gly Pro Arg Tyr Cys Tyr Ala Leu Tyr Asn Gly Thr Ala Leu Lys 1 5 10 15 TAT TTA GGA ACA TTA CCA CCT AGT GTC AAG GAA ATT GCT ATT AGT AAG 96 Tyr Leu Gly Thr Leu Pro Pro Ser Val Lys Glu Ile Ala Ile Ser Lys 20 25 30 TGG GGC CAT TTT TAT ATT AAT GGT TAC AAT TTC TTT AGC ACT TTT CCT 144 Trp Gly His Phe Tyr Ile Asn Gly Tyr Asn Phe Phe Ser Thr Phe Pro 35 40 45 ATT GAT TGT ATA TCT TTT AAT TTA ACC ACT GGT GAT AGT GGA GCA TTT 192 Ile Asp Cys Ile Ser Phe Asn Leu Thr Thr Gly Asp Ser Gly Ala Phe 50 55 60 TGG ACA ATT GCT TAC ACA TCG TAC ACT GAC GCA TTA GTA CAA GTT GAA 240 Trp Thr Ile Ala Tyr Thr Ser Tyr Thr Asp Ala Leu Val Gln Val Glu 65 70 75 80 AAC ACA GCT ATT AAA AAG GTG ACG TAT TGT AAC AGT CAC ATT AAT AAC 288 Asn Thr Ala Ile Lys Lys Val Thr Tyr Cys Asn Ser His Ile Asn Asn 85 90 95 ATT AAA TGT TCT CAA CTT ACT GCT AAT TTG CAA AAT GGA TTT TAT CCT 336 Ile Lys Cys Ser Gln Leu Thr Ala Asn Leu Gln Asn Gly Phe Tyr Pro 100 105 110 GTT GCT TCA AGT GAA GTT GGT CTT GTC AAT AAG AGT GTT GTG TTA CTA 384 Val Ala Ser Ser Glu Val Gly Leu Val Asn Lys Ser Val Val Leu Leu 115 120 125 CCT AGT TTC TAT TCA CAT ACC AGT GTT AAT ATA ACT ATT GAT CTT GGT 432 Pro Ser Phe Tyr Ser His Thr Ser Val Asn Ile Thr Ile Asp Leu Gly 130 135 140 ATG AAG CGT AGT GGT TAT GGT CAA CCC ATA GCC TCA ACA TTA AGT AAC 480 Met Lys Arg Ser Gly Tyr Gly Gln Pro Ile Ala Ser Thr Leu Ser Asn 145 150 155 160 ATC ACA CTA CCA ATG CAG GAT AAT AAC ACC GAT GTG TAC TGC ATT CGT 528 Ile Thr Leu Pro Met Gln Asp Asn Asn Thr Asp Val Tyr Cys Ile Arg 165 170 175 TCT AAC CAA TTT TCA GTT TAC GTT CAT TCC ACT TGT AAA AGT TCT TTA 576 Ser Asn Gln Phe Ser Val Tyr Val His Ser Thr Cys Lys Ser Ser Leu 180 185 190 TGG GAC GAT GTG TTT AAT TCC GAC TGC ACA GAT GTT TTA TAT GCT

ACA 624 Trp Asp Asp Val Phe Asn Ser Asp Cys Thr Asp Val Leu Tyr Ala Thr 195 200 205 GCT
GTT ATA AAA ACT GGT ACT TGT CCT TTC TCG TTT GAT AAA TTG AAC 672 Ala Val Ile Lys
Thr Gly Thr Cys Pro Phe Ser Phe Asp Lys Leu Asn 210 215 220 AAT TAC TTA ACT TTT AAC
AAG TTC TGT TTG TCA TTG AAT CCT GTT GGT 720 Asn Tyr Leu Thr Phe Asn Lys Phe Cys
Leu Ser Leu Asn Pro Val Gly 225 230 235 240 GCC AAC TGC AAG TTT GAT GTT GCC GCT CGT
ACA AGA ACC AAT GAG 765 Ala Asn Cys Lys Phe Asp Val Ala Ala Arg Thr Arg Thr Asn Glu 245
250 255 255 amino acids amino acid linear protein 41 Asp Gly Pro Arg Tyr Cys Tyr Ala Leu Tyr
Asn Gly Thr Ala Leu Lys 1 5 10 15 Tyr Leu Gly Thr Leu Pro Pro Ser Val Lys Glu Ile Ala Ile Ser Lys
20 25 30 Trp Gly His Phe Tyr Ile Asn Gly Tyr Asn Phe Phe Ser Thr Phe Pro 35 40 45 Ile Asp Cys
Ile Ser Phe Asn Leu Thr Thr Gly Asp Ser Gly Ala Phe 50 55 60 Trp Thr Ile Ala Tyr Thr Ser Tyr
Thr Asp Ala Leu Val Gln Val Glu 65 70 75 80 Asn Thr Ala Ile Lys Lys Val Thr Tyr Cys Asn Ser
His Ile Asn Asn 85 90 95 Ile Lys Cys Ser Gln Leu Thr Ala Asn Leu Gln Asn Gly Phe Tyr Pro 100
105 110 Val Ala Ser Ser Glu Val Gly Leu Val Asn Lys Ser Val Val Leu Leu 115 120 125 Pro Ser Phe
Tyr Ser His Thr Ser Val Asn Ile Thr Ile Asp Leu Gly 130 135 140 Met Lys Arg Ser Gly Tyr Gly Gln
Pro Ile Ala Ser Thr Leu Ser Asn 145 150 155 160 Ile Thr Leu Pro Met Gln Asp Asn Asn Thr Asp
Val Tyr Cys Ile Arg 165 170 175 Ser Asn Gln Phe Ser Val Tyr Val His Ser Thr Cys Lys Ser Ser Leu
180 185 190 Trp Asp Asp Val Phe Asn Ser Asp Cys Thr Asp Val Leu Tyr Ala Thr 195 200 205 Ala
Val Ile Lys Thr Gly Thr Cys Pro Phe Ser Phe Asp Lys Leu Asn 210 215 220 Asn Tyr Leu Thr Phe
Asn Lys Phe Cys Leu Ser Leu Asn Pro Val Gly 225 230 235 240 Ala Asn Cys Lys Phe Asp Val Ala
Ala Arg Thr Arg Thr Asn Glu 245 250 255 1284 base pairs nucleic acid double unknown DNA
(genomic) CDS 1..1284 42 AGG CCT CTT TTA AAA CAT GGT TTG TTG TGT ATA ACT AAA AAT
AAA ATC 48 Arg Pro Leu Leu Lys His Gly Leu Leu Cys Ile Thr Lys Asn Lys Ile 1 5 10 15 ATT GAC
TAT AAC ACG TTT ACC AGC GCA CAG TGG AGT GCC ATA TGT TTG 96 Ile Asp Tyr Asn Thr
Phe Thr Ser Ala Gln Trp Ser Ala Ile Cys Leu 20 25 30 GGT GAT GAC AGA AAA ATA CCA TTC
TCT GTC ATA CCC ACA GGT AAT GGT 144 Gly Asp Asp Arg Lys Ile Pro Phe Ser Val Ile Pro Thr
Gly Asn Gly 35 40 45 ACA AAA ATA TTT GGT CTT GAG TGG AAT GAT GAC TAT GTT ACA
GCC TAT 192 Thr Lys Ile Phe Gly Leu Glu Trp Asn Asp Asp Tyr Val Thr Ala Tyr 50 55 60 ATT
AGT GAT CGT TCT CAC CAT TTG AAC ATC AAT AAT TGG TTT AAC 240 Ile Ser Asp Arg
Ser His His Leu Asn Ile Asn Asn Asn Trp Phe Asn 65 70 75 80 AAT GTG ACA ATC CTA TAC
TCT CGA TCA AGC ACT GCT ACG TGG CAG AAG 288 Asn Val Thr Ile Leu Tyr Ser Arg Ser Ser
Thr Ala Thr Trp Gln Lys 85 90 95 AGT GCT GCA TAT GTT TAT CAA GGT GTT TCA AAT TTT
ACT TAT TAC AAG 336 Ser Ala Ala Tyr Val Tyr Gln Gly Val Ser Asn Phe Thr Tyr Tyr Lys 100
105 110 TTA AAT AAC ACC AAT GGC TTG AAA AGC TAT GAA TTG TGT GAA GAT TAT 384
Leu Asn Asn Thr Asn Gly Leu Lys Ser Tyr Glu Leu Cys Glu Asp Tyr 115 120 125 GAA TGC TGC
ACT GGC TAT GCT ACC AAC GTA TTT GCC CCG ACA GTG GGC 432 Glu Cys Cys Thr Gly Tyr
Ala Thr Asn Val Phe Ala Pro Thr Val Gly 130 135 140 GGT TAT ATA CCT GAT GGC TTC AGT
TTT AAC AAT TGG TTT ATG CTT ACA 480 Gly Tyr Ile Pro Asp Gly Phe Ser Phe Asn Asn Trp
Phe Met Leu Thr 145 150 155 160 AAC AGT TCC ACG TTT GTT AGT GGC AGA TTT GTA ACA

AAT CAA CCA TTA 528 Asn Ser Ser Thr Phe Val Ser Gly Arg Phe Val Thr Asn Gln Pro Leu 165
170 175 TTG GTT AAT TGT TTG TGG CCA GTG CCC AGT CTT GGT GTC GCA GCA CAA 576
Leu Val Asn Cys Leu Trp Pro Val Pro Ser Leu Gly Val Ala Ala Gln 180 185 190 GAA TTT TGT
TTT GAA GGT GCG CAG TTT AGC CAA TGT AAT GGT GTG TCT 624 Glu Phe Cys Phe Glu Gly
Ala Gln Phe Ser Gln Cys Asn Gly Val Ser 195 200 205 TTA AAC AAT ACA GTG GAT GTC ATT
AGA TTC AAC CTT AAT TTT ACC ACA 672 Leu Asn Asn Thr Val Asp Val Ile Arg Phe Asn Leu
Asn Phe Thr Thr 210 215 220 GAT GTA CAA TCT GGT ATG GGT GCT ACA GTA TTT TCA CTG
AAT ACA ACA 720 Asp Val Gln Ser Gly Met Gly Ala Thr Val Phe Ser Leu Asn Thr Thr 225 230
235 240 GGT GGT GTC ATT CTT GAG ATT TCT TGT TAT AAT GAT ACA GTG AGT GAG 768
Gly Gly Val Ile Leu Glu Ile Ser Cys Tyr Asn Asp Thr Val Ser Glu 245 250 255 TCA AGT TTC TAC
AGT TAT GGT GAA ATT TCA TTC GGC GTA ACT GAT GGA 816 Ser Ser Phe Tyr Ser Tyr Gly
Glu Ile Ser Phe Gly Val Thr Asp Gly 260 265 270 CCG CGT TAC TGT TAC GCA CTC TAT AAT
GGC ACG GCT CTT AAG TAT TTA 864 Pro Arg Tyr Cys Tyr Ala Leu Tyr Asn Gly Thr Ala Leu
Lys Tyr Leu 275 280 285 GGA ACA TTA CCA CCT AGT GTC AAG GAA ATT GCT ATT AGT AAG
TGG GGC 912 Gly Thr Leu Pro Pro Ser Val Lys Glu Ile Ala Ile Ser Lys Trp Gly 290 295 300 CAT
TTT TAT ATT AAT GGT TAC AAT TTC TTT AGC ACT TTT CCT ATT GAT 960 His Phe Tyr Ile
Asn Gly Tyr Asn Phe Phe Ser Thr Phe Pro Ile Asp 305 310 315 320 TGT ATA TCT TTT AAT TTA
ACC ACT GGT GAT AGT GGA GCA TTT TGG ACA 1008 Cys Ile Ser Phe Asn Leu Thr Thr Gly
Asp Ser Gly Ala Phe Trp Thr 325 330 335 ATT GCT TAC ACA TCG TAC ACT GAC GCA TTA
GTA CAA GTT GAA AAC ACA 1056 Ile Ala Tyr Thr Ser Tyr Thr Asp Ala Leu Val Gln Val Glu Asn
Thr 340 345 350 GCT ATT AAA AAG GTG ACG TAT TGT AAC AGT CAC ATT AAT AAC ATT
AAA 1104 Ala Ile Lys Lys Val Thr Tyr Cys Asn Ser His Ile Asn Asn Ile Lys 355 360 365 TGT TCT
CAA CTT ACT GCT AAT TTG CAA AAT GGA TTT TAT CCT GTT GCT 1152 Cys Ser Gln Leu Thr
Ala Asn Leu Gln Asn Gly Phe Tyr Pro Val Ala 370 375 380 TCA AGT GAA GTT GGT CTT GTC
AAT AAG AGT GTT GTG TTA CTA CCT AGT 1200 Ser Ser Glu Val Gly Leu Val Asn Lys Ser Val
Val Leu Leu Pro Ser 385 390 395 400 TTC TAT TCA CAT ACC AGT GTT AAT ATA ACT ATT
GAT CTT GGT ATG AAG 1248 Phe Tyr Ser His Thr Ser Val Asn Ile Thr Ile Asp Leu Gly Met Lys
405 410 415 CGT AGT GGT TAT GGT CAA CCC ATA GCC TCA ACA TTA 1284 Arg Ser Gly Tyr
Gly Gln Pro Ile Ala Ser Thr Leu 420 425 428 amino acids amino acid linear protein 43 Arg Pro
Leu Leu Lys His Gly Leu Leu Cys Ile Thr Lys Asn Lys Ile 1 5 10 15 Ile Asp Tyr Asn Thr Phe Thr
Ser Ala Gln Trp Ser Ala Ile Cys Leu 20 25 30 Gly Asp Asp Arg Lys Ile Pro Phe Ser Val Ile Pro Thr
Gly Asn Gly 35 40 45 Thr Lys Ile Phe Gly Leu Glu Trp Asn Asp Asp Tyr Val Thr Ala Tyr 50 55 60
Ile Ser Asp Arg Ser His His Leu Asn Ile Asn Asn Asn Trp Phe Asn 65 70 75 80 Asn Val Thr Ile
Leu Tyr Ser Arg Ser Ser Thr Ala Thr Trp Gln Lys 85 90 95 Ser Ala Ala Tyr Val Tyr Gln Gly Val
Ser Asn Phe Thr Tyr Tyr Lys 100 105 110 Leu Asn Asn Thr Asn Gly Leu Lys Ser Tyr Glu Leu Cys
Glu Asp Tyr 115 120 125 Glu Cys Cys Thr Gly Tyr Ala Thr Asn Val Phe Ala Pro Thr Val Gly 130
135 140 Gly Tyr Ile Pro Asp Gly Phe Ser Phe Asn Asn Trp Phe Met Leu Thr 145 150 155 160 Asn
Ser Ser Thr Phe Val Ser Gly Arg Phe Val Thr Asn Gln Pro Leu 165 170 175 Leu Val Asn Cys Leu

Trp Pro Val Pro Ser Leu Gly Val Ala Ala Gln 180 185 190 Glu Phe Cys Phe Glu Gly Ala Gln Phe
Ser Gln Cys Asn Gly Val Ser 195 200 205 Leu Asn Asn Thr Val Asp Val Ile Arg Phe Asn Leu Asn
Phe Thr Thr 210 215 220 Asp Val Gln Ser Gly Met Gly Ala Thr Val Phe Ser Leu Asn Thr Thr 225
230 235 240 Gly Gly Val Ile Leu Glu Ile Ser Cys Tyr Asn Asp Thr Val Ser Glu 245 250 255 Ser
Ser Phe Tyr Ser Tyr Gly Glu Ile Ser Phe Gly Val Thr Asp Gly 260 265 270 Pro Arg Tyr Cys Tyr
Ala Leu Tyr Asn Gly Thr Ala Leu Lys Tyr Leu 275 280 285 Gly Thr Leu Pro Pro Ser Val Lys Glu
Ile Ala Ile Ser Lys Trp Gly 290 295 300 His Phe Tyr Ile Asn Gly Tyr Asn Phe Phe Ser Thr Phe
Pro Ile Asp 305 310 315 320 Cys Ile Ser Phe Asn Leu Thr Thr Gly Asp Ser Gly Ala Phe Trp Thr
325 330 335 Ile Ala Tyr Thr Ser Tyr Thr Asp Ala Leu Val Gln Val Glu Asn Thr 340 345 350 Ala
Ile Lys Lys Val Thr Tyr Cys Asn Ser His Ile Asn Asn Ile Lys 355 360 365 Cys Ser Gln Leu Thr Ala
Asn Leu Gln Asn Gly Phe Tyr Pro Val Ala 370 375 380 Ser Ser Glu Val Gly Leu Val Asn Lys Ser
Val Val Leu Leu Pro Ser 385 390 395 400 Phe Tyr Ser His Thr Ser Val Asn Ile Thr Ile Asp Leu
Gly Met Lys 405 410 415 Arg Ser Gly Tyr Gly Gln Pro Ile Ala Ser Thr Leu 420 425 546 base pairs
nucleic acid double unknown DNA (genomic) CDS 1..546 44 GAT TGT ATA TCT TTT AAT TTA
ACC ACT GGT GAT AGT GGA GCA TTT TGG 48 Asp Cys Ile Ser Phe Asn Leu Thr Thr Gly Asp
Ser Gly Ala Phe Trp 1 5 10 15 ACA ATT GCT TAC ACA TCG TAC ACT GAC GCA TTA GTA CAA
GTT GAA AAC 96 Thr Ile Ala Tyr Thr Ser Tyr Thr Asp Ala Leu Val Gln Val Glu Asn 20 25 30
ACA GCT ATT AAA AAG GTG ACG TAT TGT AAC AGT CAC ATT AAT AAC ATT 144 Thr Ala Ile
Lys Lys Val Thr Tyr Cys Asn Ser His Ile Asn Asn Ile 35 40 45 AAA TGT TCT CAA CTT ACT GCT
AAT TTG CAA AAT GGA TTT TAT CCT GTT 192 Lys Cys Ser Gln Leu Thr Ala Asn Leu Gln Asn
Gly Phe Tyr Pro Val 50 55 60 GCT TCA AGT GAA GTT GGT CTT GTC AAT AAG AGT GTT GTG
TTA CTA CCT 240 Ala Ser Ser Glu Val Gly Leu Val Asn Lys Ser Val Val Leu Leu Pro 65 70 75 80
AGT TTC TAT TCA CAT ACC AGT GTT AAT ATA ACT ATT GAT CTT GGT ATG 288 Ser Phe Tyr
Ser His Thr Ser Val Asn Ile Thr Ile Asp Leu Gly Met 85 90 95 AAG CGT AGT GGT TAT GGT
CAA CCC ATA GCC TCA ACA TTA AGT AAC ATC 336 Lys Arg Ser Gly Tyr Gly Gln Pro Ile Ala
Ser Thr Leu Ser Asn Ile 100 105 110 ACA CTA CCA ATG CAG GAT AAT AAC ACC GAT GTG TAC
TGC ATT CGT TCT 384 Thr Leu Pro Met Gln Asp Asn Asn Thr Asp Val Tyr Cys Ile Arg Ser 115
120 125 AAC CAA TTT TCA GTT TAC GTT CAT TCC ACT TGT AAA AGT TCT TTA TGG 432 Asn
Gln Phe Ser Val Tyr Val His Ser Thr Cys Lys Ser Ser Leu Trp 130 135 140 GAC GAT GTG TTT
AAT TCC GAC TGC ACA GAT GTT TTA TAT GCT ACA GCT 480 Asp Asp Val Phe Asn Ser Asp
Cys Thr Asp Val Leu Tyr Ala Thr Ala 145 150 155 160 GTT ATA AAA ACT GGT ACT TGT CCT
TTC TCG TTT GAT AAA TTG AAC AAT 528 Val Ile Lys Thr Gly Thr Cys Pro Phe Ser Phe Asp Lys
Leu Asn Asn 165 170 175 TAC TTA ACT TTT AAC AAG 546 Tyr Leu Thr Phe Asn Lys 180 182
amino acids amino acid linear protein 45 Asp Cys Ile Ser Phe Asn Leu Thr Thr Gly Asp Ser Gly
Ala Phe Trp 1 5 10 15 Thr Ile Ala Tyr Thr Ser Tyr Thr Asp Ala Leu Val Gln Val Glu Asn 20 25 30
Thr Ala Ile Lys Lys Val Thr Tyr Cys Asn Ser His Ile Asn Asn Ile 35 40 45 Lys Cys Ser Gln Leu Thr
Ala Asn Leu Gln Asn Gly Phe Tyr Pro Val 50 55 60 Ala Ser Ser Glu Val Gly Leu Val Asn Lys Ser
Val Val Leu Leu Pro 65 70 75 80 Ser Phe Tyr Ser His Thr Ser Val Asn Ile Thr Ile Asp Leu Gly Met

85 90 95 Lys Arg Ser Gly Tyr Gly Gln Pro Ile Ala Ser Thr Leu Ser Asn Ile 100 105 110 Thr Leu
Pro Met Gln Asp Asn Asn Thr Asp Val Tyr Cys Ile Arg Ser 115 120 125 Asn Gln Phe Ser Val Tyr
Val His Ser Thr Cys Lys Ser Ser Leu Trp 130 135 140 Asp Asp Val Phe Asn Ser Asp Cys Thr Asp
Val Leu Tyr Ala Thr Ala 145 150 155 160 Val Ile Lys Thr Gly Thr Cys Pro Phe Ser Phe Asp Lys
Leu Asn Asn 165 170 175 Tyr Leu Thr Phe Asn Lys 180 38 base pairs nucleic acid single
unknown DNA (genomic) 46 TAAATAGGCC TTTAGTGGAC ATGCACTTTT TCAATTGG 38 39
base pairs nucleic acid single unknown DNA (genomic) 47 TTAGTAGGCC TGTCGAGGCT
ATGGGTTGAC CATAACCAC 39 37 base pairs nucleic acid single unknown DNA (genomic) 48
CAGATCCCGG GTGTACAATC TGGTATGGGT GCTACAG 37 39 base pairs nucleic acid single
unknown DNA (genomic) 49 GTGCCCCCGG GTATGATTGT GCTCGTAACT TGCCTCTTG 39 43
base pairs nucleic acid single unknown DNA (genomic) 50 AGCACCCATA CCAGATTGTA
CATCTGCAGT GAAATTAAGA TTG 43 128 amino acids amino acid unknown protein 51 Met Ile
Val Leu Val Thr Cys Leu Leu Phe Ser Tyr Asn Ser Val Il 1 5 10 15 Cys Thr Ser Asn Asn Asp Cys
Val Gln Val Asn Val Thr Gln Leu Pr 20 25 30 Gly Asn Glu Asn Ile Ile Lys Asp Phe Leu Phe His
Thr Phe Lys Gl 35 40 45 Glu Gly Ser Val Val Val Gly Gly Tyr Tyr Pro Thr Glu Val Trp Ty 50 55
60 Asn Cys Ser Arg Ser Ala Thr Thr Thr Ala Tyr Lys Asp Phe Ser As 65 70 75 80 Ile His Ala Phe
Tyr Phe Asp Met Glu Ala Met Glu Asn Ser Thr Gl 85 90 95 Asn Ala Arg Gly Lys Pro Leu Leu Val
His Val His Gly Asp Pro Va 100 105 110 Ser Ile Ile Ile Tyr Ile Ser Ala Tyr Arg Asp Asp Val Gln
Gly Ar 115 120 125 1101 amino acids amino acid unknown protein 52 Asp Val Gln Ser Gly Met
Gly Ala Thr Val Phe Ser Leu Asn Thr Thr 1 5 10 15 Gly Gly Val Ile Leu Glu Ile Ser Cys Tyr Asn
Asp Thr Val Ser Glu 20 25 30 Ser Ser Phe Tyr Ser Tyr Gly Glu Ile Ser Phe Gly Val Thr Asp Gly 35
40 45 Pro Arg Tyr Cys Tyr Ala Leu Tyr Asn Gly Thr Ala Leu Lys Tyr Leu 50 55 60 Gly Thr Leu
Pro Pro Ser Val Lys Glu Ile Ala Ile Ser Lys Trp Gly 65 70 75 80 His Phe Tyr Ile Asn Gly Tyr Asn
Phe Phe Ser Thr Phe Pro Ile Asp 85 90 95 Cys Ile Ser Phe Asn Leu Thr Thr Gly Asp Ser Gly Ala
Phe Trp Thr 100 105 110 Ile Ala Tyr Thr Ser Tyr Thr Asp Ala Leu Val Gln Val Glu Asn Thr 115
120 125 Ala Ile Lys Lys Val Thr Tyr Cys Asn Ser His Ile Asn Asn Ile Lys 130 135 140 Cys Ser Gln
Leu Thr Ala Asn Leu Gln Asn Gly Phe Tyr Pro Val Ala 145 150 155 160 Ser Ser Glu Val Gly Leu
Val Asn Lys Ser Val Val Leu Leu Pro Ser 165 170 175 Phe Tyr Ser His Thr Ser Val Asn Ile Thr Ile
Asp Leu Gly Met Lys 180 185 190 Arg Ser Gly Tyr Gly Gln Pro Ile Ala Ser Thr Leu Ser Asn Ile
Thr 195 200 205 Leu Pro Met Gln Asp Asn Asn Thr Asp Val Tyr Cys Ile Arg Ser Asn 210 215 220
Gln Phe Ser Val Tyr Val His Ser Thr Cys Lys Ser Ser Leu Trp Asp 225 230 235 240 Asp Val Phe
Asn Ser Asp Cys Thr Asp Val Leu Tyr Ala Thr Ala Val 245 250 255 Ile Lys Thr Gly Thr Cys Pro
Phe Ser Phe Asp Lys Leu Asn Asn Tyr 260 265 270 Leu Thr Phe Asn Lys Phe Cys Leu Ser Leu
Asn Pro Val Gly Ala Asn 275 280 285 Cys Lys Phe Asp Val Ala Ala Arg Thr Arg Thr Asn Glu Gln
Val Val 290 295 300 Arg Ser Leu Tyr Val Ile Tyr Glu Glu Gly Asp Asn Ile Val Gly Val 305 310 315
320 Pro Ser Asp Asn Ser Gly Leu His Asp Leu Ser Val Leu His Leu Asp 325 330 335 Ser Cys Thr
Asp Tyr Asn Ile Tyr Gly Arg Thr Gly Val Gly Ile Ile 340 345 350 Arg Gln Thr Asn Ser Thr Leu
Leu Ser Gly Leu Tyr Tyr Thr Ser Leu 355 360 365 Ser Gly Asp Leu Leu Gly Phe Lys Asn Val Ser

Asp Gly Val Ile Tyr 370 375 380 Ser Val Thr Pro Cys Asp Val Ser Ala Gln Ala Ala Val Ile Asp Gly
385 390 395 400 Ala Ile Val Gly Ala Met Thr Ser Ile Asn Ser Glu Met Leu Gly Leu 405 410 415
Thr His Trp Thr Thr Thr Pro Asn Phe Tyr Tyr Tyr Ser Ile Tyr Asn 420 425 430 Tyr Thr Asn Glu
Arg Thr Arg Gly Thr Ala Ile Asp Ser Asn Asp Val 435 440 445 Asp Cys Glu Pro Ile Ile Thr Tyr Ser
Asn Ile Gly Val Cys Lys Asn 450 455 460 Gly Ala Leu Val Phe Ile Asn Val Thr His Ser Asp Gly
Asp Val Gln 465 470 475 480 Pro Ile Ser Thr Gly Asn Val Thr Ile Pro Thr Asn Phe Thr Ile Ser
485 490 495 Val Gln Val Glu Tyr Ile Gln Val Tyr Thr Thr Pro Val Ser Ile Asp 500 505 510 Cys
Ser Arg Tyr Val Cys Asn Gly Asn Pro Arg Cys Asn Lys Leu Leu 515 520 525 Thr Gln Tyr Val Ser
Ala Cys Gln Thr Ile Glu Gln Ala Leu Ala Met 530 535 540 Gly Ala Arg Leu Glu Asn Met Glu Ile
Asp Ser Met Leu Phe Val Ser 545 550 555 560 Glu Asn Ala Leu Lys Leu Ala Ser Val Glu Ala Phe
Asn Ser Thr Glu 565 570 575 Thr Leu Asp Pro Ile Tyr Lys Glu Trp Pro Asn Ile Gly Gly Ser Trp
580 585 590 Leu Gly Gly Leu Lys Asp Ile Leu Pro Ser His Asn Ser Lys Arg Lys 595 600 605 Tyr
Arg Ser Ala Ile Glu Asp Leu Leu Phe Asp Lys Val Val Thr Ser 610 615 620 Gly Leu Gly Thr Val
Asp Glu Asp Tyr Lys Arg Cys Thr Gly Gly Tyr 625 630 635 640 Asp Ile Ala Asp Leu Val Cys Ala
Gln Tyr Tyr Asn Gly Ile Met Val 645 650 655 Leu Pro Gly Val Ala Asn Asp Asp Lys Met Ala Met
Tyr Thr Ala Ser 660 665 670 Leu Ala Gly Gly Ile Thr Leu Gly Ala Leu Gly Gly Gly Ala Val Ser 675
680 685 Ile Pro Phe Ala Ile Ala Val Gln Ala Arg Leu Asn Tyr Val Ala Leu 690 695 700 Gln Thr
Asp Val Leu Ser Lys Asn Gln Gln Ile Leu Ala Asn Ala Phe 705 710 715 720 Asn Gln Ala Ile Gly
Asn Ile Thr Gln Ala Phe Gly Lys Val Asn Asp 725 730 735 Ala Ile His Gln Thr Ser Gln Gly Leu
Ala Thr Val Ala Lys Ala Leu 740 745 750 Ala Lys Val Gln Asp Val Val Asn Thr Gln Gly Gln Ala
Leu Ser His 755 760 765 Leu Thr Val Gln Leu Gln Asn Asn Phe Gln Ala Ile Ser Ser Ser Ile 770
775 780 Ser Asp Ile Tyr Asn Arg Leu Asp Glu Leu Ser Ala Asp Ala Gln Val 785 790 795 800 Asp
Arg Leu Ile Thr Gly Arg Leu Thr Ala Leu Asn Ala Phe Val Ser 805 810 815 Gln Thr Leu Thr Arg
Gln Ala Glu Val Arg Ala Ser Arg Gln Leu Ala 820 825 830 Lys Asp Lys Val Asn Glu Cys Val Arg
Ser Gln Ser Gln Arg Phe Gly 835 840 845 Phe Cys Gly Asn Gly Thr His Leu Phe Ser Leu Ala Asn
Ala Ala Pro 850 855 860 Asn Gly Met Ile Phe Phe His Thr Val Leu Leu Pro Thr Ala Tyr Glu 865
870 875 880 Thr Val Thr Ala Trp Ser Gly Ile Cys Ala Ser Asp Gly Asp Arg Thr 885 890 895 Phe
Gly Leu Val Val Lys Asp Val Gln Leu Thr Leu Phe Arg Asn Leu 900 905 910 Asp Asp Lys Phe Tyr
Leu Thr Pro Arg Thr Met Tyr Gln Pro Arg Val 915 920 925 Ala Thr Ser Ser Asp Phe Val Gln Ile
Glu Gly Cys Asp Val Leu Phe 930 935 940 Val Asn Ala Thr Val Ile Asp Leu Pro Ser Ile Ile Pro
Asp Tyr Ile 945 950 955 960 Asp Ile Asn Gln Thr Val Gln Asp Ile Leu Glu Asn Phe Arg Pro Asn
965 970 975 Trp Thr Val Pro Glu Leu Pro Leu Asp Ile Phe Asn Ala Thr Tyr Leu 980 985 990 Asn
Leu Thr Gly Glu Ile Asn Asp Leu Glu Phe Arg Ser Glu Lys Leu 995 1000 1005 His Asn Thr Thr
Val Glu Leu Ala Ile Leu Ile Asp Asn Ile Asn Asn 1010 1015 1020 Thr Leu Val Asn Leu Glu Trp
Leu Asn Arg Ile Glu Thr Tyr Val Lys 1025 1030 1035 1040 Trp Pro Trp Tyr Val Trp Leu Leu Ile
Gly Leu Val Val Ile Phe Cys 1045 1050 1055 Ile Pro Ile Leu Leu Phe Cys Cys Cys Ser Thr Gly Cys
Cys Gly Cys 1060 1065 1070 Ile Gly Cys Leu Gly Ser Cys Cys His Ser Ile Cys Ser Arg Arg Arg
1075 1080 1085 Phe Glu Ser Tyr Glu Pro Ile Glu Lys Val His Val His 1090 1095 1100 362 amino

acids amino acid unknown protein 53 Met Ile Val Leu Val Thr Cys Leu Leu Phe Ser Tyr Asn Ser Val Ile 1 5 10 15 Cys Thr Ser Asn Asn Asp Cys Val Gln Val Asn Val Thr Gln Leu Pro 20 25 30 Gly Asn Glu Asn Ile Ile Lys Asp Phe Leu Phe His Thr Phe Lys Glu 35 40 45 Glu Gly Ser Val Val Val Gly Gly Tyr Tyr Pro Thr Glu Val Trp Tyr 50 55 60 Asn Cys Ser Arg Ser Ala Thr Thr Thr Ala Tyr Lys Asp Phe Ser Asn 65 70 75 80 Ile His Ala Phe Tyr Phe Asp Met Glu Ala Met Glu Asn Ser Thr Gly 85 90 95 Asn Ala Arg Gly Lys Pro Leu Leu Val His Val His Gly Asp Pro Val 100 105 110 Ser Ile Ile Ile Tyr Ile Ser Ala Tyr Arg Asp Asp Val Gln Gly Arg 115 120 125 Pro Leu Leu Lys His Gly Leu Leu Cys Ile Thr Lys Asn Lys Ile Ile 130 135 140 Asp Tyr Asn Thr Phe Thr Ser Ala Gln Trp Ser Ala Ile Cys Leu Gly 145 150 155 160 Asp Asp Arg Lys Ile Pro Phe Ser Val Ile Pro Thr Gly Asn Gly Thr 165 170 175 Lys Ile Phe Gly Leu Glu Trp Asn Asp Asp Tyr Val Thr Ala Tyr Ile 180 185 190 Ser Asp Arg Ser His His Leu Asn Ile Asn Asn Asn Trp Phe Asn Asn 195 200 205 Val Thr Ile Leu Tyr Ser Arg Ser Ser Thr Ala Thr Trp Gln Lys Ser 210 215 220 Ala Ala Tyr Val Tyr Gln Gly Val Ser Asn Phe Thr Tyr Tyr Lys Leu 225 230 235 240 Asn Asn Thr Asn Gly Leu Lys Ser Tyr Glu Leu Cys Glu Asp Tyr Glu 245 250 255 Cys Cys Thr Gly Tyr Ala Thr Asn Val Phe Ala Pro Thr Val Gly Gly 260 265 270 Tyr Ile Pro Asp Gly Phe Ser Phe Asn Asn Trp Phe Met Leu Thr Asn 275 280 285 Ser Ser Thr Phe Val Ser Gly Arg Phe Val Thr Asn Gln Pro Leu Leu 290 295 300 Val Asn Cys Leu Trp Pro Val Pro Ser Leu Gly Val Ala Ala Gln Glu 305 310 315 320 Phe Cys Phe Glu Gly Ala Gln Phe Ser Gln Cys Asn Gly Val Ser Leu 325 330 335 Asn Asn Thr Val Asp Val Ile Arg Phe Asn Leu Asn Phe Thr Thr Asp 340 345 350 Val Gln Ser Gly Met Gly Ala Thr Val Phe 355 360 1101 amino acids amino acid unknown protein 54 Ala Ala Tyr Val Tyr Gln Gly Val Ser Asn Phe Thr Tyr Tyr Lys Leu 1 5 10 15 Asn Asn Thr Asn Gly Leu Lys Ser Tyr Glu Leu Cys Glu Asp Tyr Glu 20 25 30 Cys Cys Thr Gly Tyr Ala Thr Asn Val Phe Ala Pro Thr Val Gly Gly 35 40 45 Tyr Ile Pro Asp Gly Phe Ser Phe Asn Asn Trp Phe Met Leu Thr Asn 50 55 60 Ser Ser Thr Phe Val Ser Gly Arg Phe Val Thr Asn Gln Pro Leu Leu 65 70 75 80 Val Asn Cys Leu Trp Pro Val Pro Ser Leu Gly Val Ala Ala Gln Glu 85 90 95 Phe Cys Phe Glu Gly Ala Gln Phe Ser Gln Cys Asn Gly Val Ser Leu 100 105 110 Asn Asn Thr Val Asp Val Ile Arg Phe Asn Leu Asn Phe Thr Thr Asp 115 120 125 Val Gln Ser Gly Met Gly Ala Thr Val Phe Ser Leu Asn Thr Thr Gly 130 135 140 Gly Val Ile Leu Glu Ile Ser Cys Tyr Asn Asp Thr Val Ser Glu Ser 145 150 155 160 Ser Phe Tyr Ser Tyr Gly Glu Ile Ser Phe Gly Val Thr Asp Gly Pro 165 170 175 Arg Tyr Cys Tyr Ala Leu Tyr Asn Gly Thr Ala Leu Lys Tyr Leu Gly 180 185 190 Thr Leu Pro Pro Ser Val Lys Glu Ile Ala Ile Ser Lys Trp Gly His 195 200 205 Phe Tyr Ile Asn Gly Tyr Asn Phe Phe Ser Thr Phe Pro Ile Asp Cys 210 215 220 Ile Ser Phe Asn Leu Thr Thr Gly Asp Ser Gly Ala Phe Trp Thr Ile 225 230 235 240 Ala Tyr Thr Ser Tyr Thr Asp Ala Leu Val Gln Val Glu Asn Thr Ala 245 250 255 Ile Lys Lys Val Thr Tyr Cys Asn Ser His Ile Asn Asn Ile Lys Cys 260 265 270 Ser Gln Leu Thr Ala Asn Leu Gln Asn Gly Phe Tyr Pro Val Ala Ser 275 280 285 Ser Glu Val Gly Leu Val Asn Lys Ser Val Val Leu Leu Pro Ser Phe 290 295 300 Tyr Ser His Thr Ser Val Asn Ile Thr Ile Asp Leu Gly Met Lys Arg 305 310 315 320 Ser Gly Tyr Gly Gln Pro Ile Ala Ser Thr Leu Ser Asn Ile Thr Leu 325 330 335 Pro Met Gln Asp Asn Asn Thr Asp Val Tyr Cys Ile Arg Ser Asn Gln 340 345 350 Phe Ser Val Tyr Val His Ser Thr Cys Lys Ser Ser Leu Trp Asp Asp 355

360 365 Val Phe Asn Ser Asp Cys Thr Asp Val Leu Tyr Ala Thr Ala Val Ile 370 375 380 Lys Thr
Gly Thr Cys Pro Phe Ser Phe Asp Lys Leu Asn Asn Tyr Leu 385 390 395 400 Thr Phe Asn Lys
Phe Cys Leu Ser Leu Asn Pro Val Gly Ala Asn Cys 405 410 415 Lys Phe Asp Val Ala Ala Arg Thr
Arg Thr Asn Glu Gln Val Val Arg 420 425 430 Ser Leu Tyr Val Ile Tyr Glu Glu Gly Asp Asn Ile
Val Gly Val Pro 435 440 445 Ser Asp Asn Ser Gly Leu His Asp Leu Ser Val Leu His Leu Asp Ser
450 455 460 Cys Thr Asp Tyr Asn Ile Tyr Gly Arg Thr Gly Val Gly Ile Ile Arg 465 470 475 480
Gln Thr Asn Ser Thr Leu Leu Ser Gly Leu Tyr Tyr Thr Ser Leu Ser 485 490 495 Gly Asp Leu Leu
Gly Phe Lys Asn Val Ser Asp Gly Val Ile Tyr Ser 500 505 510 Val Thr Pro Cys Asp Val Ser Ala
Gln Ala Ala Val Ile Asp Gly Ala 515 520 525 Ile Val Gly Ala Met Thr Ser Ile Asn Ser Glu Met Leu
Gly Leu Thr 530 535 540 His Trp Thr Thr Thr Pro Asn Phe Tyr Tyr Tyr Ser Ile Tyr Asn Tyr 545
550 555 560 Thr Asn Glu Arg Thr Arg Gly Thr Ala Ile Asp Ser Asn Asp Val Asp 565 570 575 Cys
Glu Pro Ile Ile Thr Tyr Ser Asn Ile Gly Val Cys Lys Asn Gly 580 585 590 Ala Leu Val Phe Ile Asn
Val Thr His Ser Asp Gly Asp Val Gln Pro 595 600 605 Ile Ser Thr Gly Asn Val Thr Ile Pro Thr
Asn Phe Thr Ile Ser Val 610 615 620 Gln Val Glu Tyr Ile Gln Val Tyr Thr Thr Pro Val Ser Ile Asp
Cys 625 630 635 640 Ser Arg Tyr Val Cys Asn Gly Asn Pro Arg Cys Asn Lys Leu Leu Thr 645 650
655 Gln Tyr Val Ser Ala Cys Gln Thr Ile Glu Gln Ala Leu Ala Met Gly 660 665 670 Ala Arg Leu
Glu Asn Met Glu Ile Asp Ser Met Leu Phe Val Ser Glu 675 680 685 Asn Ala Leu Lys Leu Ala Ser
Val Glu Ala Phe Asn Ser Thr Glu Thr 690 695 700 Leu Asp Pro Ile Tyr Lys Glu Trp Pro Asn Ile
Gly Gly Ser Trp Leu 705 710 715 720 Gly Gly Leu Lys Asp Ile Leu Pro Ser His Asn Ser Lys Arg
Lys Tyr 725 730 735 Arg Ser Ala Ile Glu Asp Leu Leu Phe Asp Lys Val Val Thr Ser Gly 740 745
750 Leu Gly Thr Val Asp Glu Asp Tyr Lys Arg Cys Thr Gly Gly Tyr Asp 755 760 765 Ile Ala Asp
Leu Val Cys Ala Gln Tyr Tyr Asn Gly Ile Met Val Leu 770 775 780 Pro Gly Val Ala Asn Asp Asp
Lys Met Ala Met Tyr Thr Ala Ser Leu 785 790 795 800 Ala Gly Gly Ile Thr Leu Gly Ala Leu Gly
Gly Gly Ala Val Ser Ile 805 810 815 Pro Phe Ala Ile Ala Val Gln Ala Arg Leu Asn Tyr Val Ala Leu
Gln 820 825 830 Thr Asp Val Leu Ser Lys Asn Gln Gln Ile Leu Ala Asn Ala Phe Asn 835 840 845
Gln Ala Ile Gly Asn Ile Thr Gln Ala Phe Gly Lys Val Asn Asp Ala 850 855 860 Ile His Gln Thr Ser
Gln Gly Leu Ala Thr Val Ala Lys Ala Leu Ala 865 870 875 880 Lys Val Gln Asp Val Val Asn Thr
Gln Gly Gln Ala Leu Ser His Leu 885 890 895 Thr Val Gln Leu Gln Asn Asn Phe Gln Ala Ile Ser
Ser Ser Ile Ser 900 905 910 Asp Ile Tyr Asn Arg Leu Asp Glu Leu Ser Ala Asp Ala Gln Val Asp
915 920 925 Arg Leu Ile Thr Gly Arg Leu Thr Ala Leu Asn Ala Phe Val Ser Gln 930 935 940 Thr
Leu Thr Arg Gln Ala Glu Val Arg Ala Ser Arg Gln Leu Ala Lys 945 950 955 960 Asp Lys Val Asn
Glu Cys Val Arg Ser Gln Ser Gln Arg Phe Gly Phe 965 970 975 Cys Gly Asn Gly Thr His Leu Phe
Ser Leu Ala Asn Ala Ala Pro Asn 980 985 990 Gly Met Ile Phe Phe His Thr Val Leu Leu Pro Thr
Ala Tyr Glu Thr 995 1000 1005 Val Thr Ala Trp Ser Gly Ile Cys Ala Ser Asp Gly Asp Arg Thr Phe
1010 1015 1020 Gly Leu Val Val Lys Asp Val Gln Leu Thr Leu Phe Arg Asn Leu Asp 1025 1030
1035 1040 Asp Lys Phe Tyr Leu Thr Pro Arg Thr Met Tyr Gln Pro Arg Val Ala 1045 1050 1055
Thr Ser Ser Asp Phe Val Gln Ile Glu Gly Cys Asp Val Leu Phe Val 1060 1065 1070 Asn Ala Thr
Val Ile Asp Leu Pro Ser Ile Ile Pro Asp Tyr Ile Asp 1075 1080 1085 Ile Asn Gln Thr Val Gln Asp

Ile Leu Glu Asn Phe Arg 1090 1095 1100 701 base pairs nucleic acid double unknown DNA (genomic) 55 TCAACCATTA TTGGTTAATT GTTTGTGGCC AGTGCCCAGT CTTGGTGTCTG CAGCACAAGA 60 ATTTTGT TTTT GAAGGTGCGC AGTTTAGCCA ATGTAATGGT GTGTCTTTAA ACAATACAGT 120 GGATGTCATT AGATTCAACC TTAATTTTAC CACAGATGTA CAATCTGGTA TGGGTGCTAC 180 AGTATTTTCA CTGAATACAA CAGGTGGTGT CATTCTTGAG ATTTCTTGTT ATAATGATAC 240 AGTGAGTGAG TCAAGTTTCT ACAGTTATGG TGAAATTTCA TTCGGCGTAA CTGATGGACC 300 GCGTTACTGT TACGCACTCT ATAATGGCAC GGCTCTTAAG TATTTAGGAA CATTACCACC 360 TAGTGTCAAG GAAATTGCTA TTAGTAAGTG GGGCCATTTT TATATTAATG GTTACAATTT 420 CTTTAGCACT TTTCTATTG ATTGTATATC TTTTAATTTA ACCACTGGTG ATAGTGGAGC 480 ATTTTGGACA ATTGCTTACA CATCGTACAC TGACGCATTA GTACAAGTTG AAAACACAGC 540 TATTA AAAAAG GTGACGTATT GTAACAGTCA CATTAAATAAC ATTAATGTT CTCAACTTAC 600 TGCTAATTTG CAAAATGGAT TTTATCCTGT TGCTTCAAGT GAAGTTGGTC TTGTCAATAA 660 GAGTGTTGTG TTA CTACCTA GTTTCTATTC ACATACCAGT G 701 1401 base pairs nucleic acid double unknown DNA (genomic) 56 AGCACCGGTA ATGTCACGAT ACCTACAAAT TTTACCATAT CTGTGCAAGT TGAGTACATT 60 CAGGTTTACA CTACACCGGT GTCAATAGAT TGTTC AAGGT ACGTTTGCAA TGGTAACCCT 120 AGATGCAATA AATTGTTAAC GCAATACGTT TCTGCATGTC AACTATTGA GCAAGCACTT 180 GCAATGGGTG CCAGACTTGA AAACATGGAG ATTGATTCCA TGTTGTTTGT TTCGGAAAAT 240 GCCCTTAAAT TGGCATCTGT TGAAGCATT C AATAGTACGG AACTTTAGA TCCTATTTAC 300 AAAGAATGGC CTAACATTGG TGGTTCTTGG CTAGGAGGTT TAAAAGACAT ATTGCCATCT 360 CACAACAGCA AACGTAAGTA CCGGTCGGCT ATAGAAGATT TGCTTTTTGA TAAGGTTGTA 420 ACATCTGGCT TAGGTACAGT TGATGAAGAT TATAAACGTT GTACAGGTGG TTATGACATA 480 GCTGACTTAG TGTGTGCACA ATATTACAAT GGCATCATGG TGCTACCTGG TGTAGCTAAT 540 GATGACAAGA TGGCTATGTA CACTGCATCT CTTGCAGGTG GTATAACATT AGGTGCACTT 600 GGTGGTGGCG CAGTGTCTAT ACCTTTTGCA ATAGCAGTTC AAGCCAGACT TAATTATGTT 660 GCTCTACAAA CTGATGTATT GAGCAAGAAC CAGCAGATCC TGGCTAATGC TTTCAATCAA 720 GCTATTGGTA ACATTACACA GGCATTTGGT AAGGTTAATG ATGCTATACA TCAAACGTCA 780 CAAGGTCTTG CTA CTGTTGC TAAAGCATTG GCAAAAGTGC AAGATGTTGT TAACACACAA 840 GGGCAAGCTT TAAGCCACCT AACAGTACAA TTGCAAAATA ATTTCCAAGC CATTAGTAGT 900 TCCATTAGTG ACATTTATAA CAGGCTTGAT GAATTGAGTG CTGATGCACA AGTTGACAGG 960 CTGATTACAG GAAGACTTAC AGCACTTAAT GCATTTGTGT CTCAGACTTT AACCAGACAA 1020 GCAGAGGTTA GGGCTAGCAG ACAGCTTGCT AAAGACAAGG TAAATGAATG CGTTAGGTCT 1080 CAATCTCAGA GATTTGGATT CTGTGGTAAT GGTACACATT TATTTTCACT TGCAAATGCA 1140 GCACCAAATG GCATGATCTT CTTTCACACA GTGCTATTAC CAACAGCTTA TGAAACCGTG

1200 ACGGCCTGGT CAGGTATTTG TGCATCAGAT GGCGATCGTA CTTTTGGACT
TGTTGTTAAG 1260 GATGTCCAGT TGACGCTGTT TCGCAATCTA GATGACAAAT
TCTATTTGAC TCCCAGAACT 1320 ATGTATCAGC CTAGAGTTGC AACTAGTTCT
GATTTTGTTC AAATTGAAGG ATGTGATGTG 1380 TTGTTTGTTA ATGCAACTGT A 1401 250
amino acids amino acid unknown protein 57 Met Ile Val Leu Val Thr Cys Leu Leu Phe Ser Tyr
Asn Ser Val Ile 1 5 10 15 Cys Thr Ser Asn Asn Asp Cys Val Gln Val Asn Val Thr Gln Leu Pro 20 25
30 Gly Asn Glu Asn Ile Ile Lys Asp Phe Leu Phe His Thr Phe Lys Glu 35 40 45 Glu Gly Ser Val
Val Val Gly Gly Tyr Tyr Pro Thr Glu Val Trp Tyr 50 55 60 Asn Cys Ser Arg Ser Ala Thr Thr Thr
Ala Tyr Lys Asp Phe Ser Asn 65 70 75 80 Ile His Ala Phe Tyr Phe Asp Met Glu Ala Met Glu Asn
Ser Thr Gly 85 90 95 Asn Ala Arg Gly Lys Pro Leu Leu Val His Val His Gly Asp Pro Val 100 105
110 Ser Ile Ile Ile Tyr Ile Ser Ala Tyr Arg Asp Asp Val Gln Gly Arg 115 120 125 Pro Leu Leu Lys
His Gly Leu Leu Cys Ile Thr Lys Asn Lys Ile Ile 130 135 140 Asp Tyr Asn Thr Phe Thr Ser Ala Gln
Trp Ser Ala Ile Cys Leu Gly 145 150 155 160 Asp Asp Arg Lys Ile Pro Phe Ser Val Ile Pro Thr Gly
Asn Gly Thr 165 170 175 Lys Ile Phe Gly Leu Glu Trp Asn Asp Asp Tyr Val Thr Ala Tyr Ile 180
185 190 Ser Asp Arg Ser His His Leu Asn Ile Asn Asn Asn Trp Phe Asn Asn 195 200 205 Val Thr
Ile Leu Tyr Ser Arg Ser Ser Thr Ala Thr Trp Gln Lys Ser 210 215 220 Ala Ala Tyr Val Tyr Gln Gly
Val Ser Asn Phe Thr Tyr Tyr Lys Le 225 230 235 240 Asn Asn Thr Asn Gly Leu Lys Ser Tyr Glu
245 250 201 amino acids amino acid unknown protein 58 Ser Phe Asn Leu Thr Thr Gly Asp Ser
Gly Ala Phe Trp Thr Ile Ala 1 5 10 15 Tyr Thr Ser Tyr Thr Asp Ala Leu Val Gln Val Glu Asn Thr
Ala Ile 20 25 30 Lys Lys Val Thr Tyr Cys Asn Ser His Ile Asn Asn Ile Lys Cys Ser 35 40 45 Gln
Leu Thr Ala Asn Leu Gln Asn Gly Phe Tyr Pro Val Ala Ser Ser 50 55 60 Glu Val Gly Leu Val Asn
Lys Ser Val Val Leu Leu Pro Ser Phe Tyr 65 70 75 80 Ser His Thr Ser Val Asn Ile Thr Ile Asp Leu
Gly Met Lys Arg Ser 85 90 95 Gly Tyr Gly Gln Pro Ile Ala Ser Thr Leu Ser Asn Ile Thr Leu Pro
100 105 110 Met Gln Asp Asn Asn Thr Asp Val Tyr Cys Ile Arg Ser Asn Gln Phe 115 120 125 Ser
Val Tyr Val His Ser Thr Cys Lys Ser Ser Leu Trp Asp Asp Val 130 135 140 Phe Asn Ser Asp Cys
Thr Asp Val Leu Tyr Ala Thr Ala Val Ile Lys 145 150 155 160 Thr Gly Thr Cys Pro Phe Ser Phe
Asp Lys Leu Asn Asn Tyr Leu Thr 165 170 175 Phe Asn Lys Phe Cys Leu Ser Leu Asn Pro Val Gly
Ala Asn Cys Lys 180 185 190 Phe Asp Val Ala Ala Arg Thr Arg Thr 195 200 251 amino acids
amino acid unknown protein 59 Glu Asn Met Glu Ile Asp Ser Met Leu Phe Val Ser Glu Asn Ala
Leu 1 5 10 15 Lys Leu Ala Ser Val Glu Ala Phe Asn Ser Thr Glu Thr Leu Asp Pro 20 25 30 Ile Tyr
Lys Glu Trp Pro Asn Ile Gly Gly Ser Trp Leu Gly Gly Leu 35 40 45 Lys Asp Ile Leu Pro Ser His
Asn Ser Lys Arg Lys Tyr Arg Ser Ala 50 55 60 Ile Glu Asp Leu Leu Phe Asp Lys Val Val Thr Ser
Gly Leu Gly Thr 65 70 75 80 Val Asp Glu Asp Tyr Lys Arg Cys Thr Gly Gly Tyr Asp Ile Ala Asp 85
90 95 Leu Val Cys Ala Gln Tyr Tyr Asn Gly Ile Met Val Leu Pro Gly Val 100 105 110 Ala Asn Asp
Asp Lys Met Ala Met Tyr Thr Ala Ser Leu Ala Gly Gly 115 120 125 Ile Thr Leu Gly Ala Leu Gly
Gly Gly Ala Val Ser Ile Pro Phe Ala 130 135 140 Ile Ala Val Gln Ala Arg Leu Asn Tyr Val Ala Leu
Gln Thr Asp Val 145 150 155 160 Leu Ser Lys Asn Gln Gln Ile Leu Ala Asn Ala Phe Asn Gln Ala
Ile 165 170 175 Gly Asn Ile Thr Gln Ala Phe Gly Lys Val Asn Asp Ala Ile His Gln 180 185 190 Thr

Ser Gln Gly Leu Ala Thr Val Ala Lys Ala Leu Ala Lys Val Gln 195 200 205 Asp Val Val Asn Thr
 Gln Gly Gln Ala Leu Ser His Leu Thr Val Gln 210 215 220 Leu Gln Asn Asn Phe Gln Ala Ile Ser
 Ser Ser Ile Ser Asp Ile Tyr 225 230 235 240 Asn Arg Leu Asp Glu Leu Ser Ala Asp Ala Gln 245
 250

Claims

1. A vaccine composition comprising an isolated S protein of canine coronavirus (CCV) strain 1-71 (SEQ ID NO:2), useful to immunize a dog against CCV.
2. A vaccine composition according to claim 1 wherein said S protein further comprises a fusion protein.
3. A vaccine composition according to claim 1 further comprising an immunogenic amount of one or more additional antigens.
4. A method of treating infection in dogs by canine coronavirus, comprising treating a dog with a vaccine composition of claim 1.

Referenced Cited

U.S. Patent Documents

4567042	January 28, 1986	Acree et al.
4567043	January 28, 1986	Acree et al.
4824785	April 25, 1989	Acree et al.
4904468	February 27, 1990	Gill et al.
5013663	May 7, 1991	Acree et al.
5047238	September 10, 1991	Acree et al.

Foreign Patent Documents

0329264	August 1987	EP

0264979	April 1988	EP
0278541	August 1988	EP
0310316	April 1989	EP
0376744	July 1990	EP
0396193	November 1990	EP
0510773	October 1992	EP

Other references

- Jacobs et al., *Virus Research*, 8 (1987) 363-371, "The nucleotide sequence of the peplomer gene of porcine transmissible gastroenteritis virus (TGEV): comparison with the sequence of the peplomer protein of feline infectious peritonitis virus (FIPV)".*
- de Groot et al., *J. Gen. Virology*, 68(1987) 2639-2646, "cDNA Cloning and Sequence Analysis of the Gene Encoding the Peplomer Protein of Feline Infectious Peritonitis Virus".*
- Luckow et al., *Biotechnology*, 6 (1988) 47-55, "Trends in the Development of Baculovirus Expression Vectors".*
- Binn et al., 1974, "Recovery and characterization of a coronavirus from military dogs with diarrhea", in: *Proc. 78th Ann. Mtg. U.S. Animal Health Assoc.*, Roanoke, Va., pp. 359-366.
- Jacobs et al., 1987 "The nucleotide sequence of the peplomer gene of porcine transmissible gastroenteritis virus (TGEV): comparison with the sequence of the peplomer protein of feline infectious peritonitis virus (FIPV)", *Virus Res.* 8:363-371.
- Takahashi et al., 1990, "Induction of CD8 + cytotoxic T cells by immunization with purified HIV-1 envelope protein in ISCOMs", *Nature* 344:873-875.
- Vennema et al., 1990, "Early death after feline infectious peritonitis virus challenge due to recombinant vaccinia virus immunization", *J. Virology* 64:1407-1409.
- Spaan, 1990, "Progress towards a coronavirus recombinant DNA vaccine", in: *Coronaviruses and their diseases*, Cavanagh and Brown (eds), Plenum Press, N.Y. pp. 201-203.
- Young et al., 1983, "Efficient isolation of genes by using antibody probes", *Proc. Natl. Acad. Sci. USA* 80:1194-1198.
- Lerner et al., 1983, "The development of synthetic vaccines", in: *The biology of immunologic diseases*, Dixon and Fisher (eds), Sinauer Associates Publishing Co., Ma., pp. 331-338.
- Raabe et al., 1990, "Nucleotide sequence of the gene encoding the spike glycoprotein of

human coronavirus HCV 229E”, J. Gen. Virology 71:1065-1073.

- Hohdatsu et al., 1991, “Characterization of monoclonal antibodies against feline infectious peritonitis virus type II and antigenic relationship between feline, porcine, and canine coronaviruses”, Arch. Virology 117:85-95.
- Bae et al., 1991, “Differentiation of transmissible gastroenteritis virus from porcine respiratory coronavirus and other antigenically related coronaviruses by using cDNA probes specific for the 5’ region of the S glycoprotein gene”, J. Clin. Microbiology 29:215-218.

Patent History

Patent number: 6372224

Type: Grant

Filed: Jan 28, 2000

Date of Patent: Apr 16, 2002

Assignee: Pfizer Inc. (New York, NY)

Inventors: Timothy J. Miller (Lincoln, NE), Sharon Klepfer (Broomall, PA), Albert Paul Reed (Exton, PA), Elaine V. Jones (Wynnewood, PA)

Primary Examiner: Laurie Scheiner

Attorney, Agent or Law Firms: Peter C. Richardson, Paul H. Ginsburg, E. Victor Donahue

Application Number: 09/494,151

Classifications

Current U.S. Class: Coronaviridae (e.g., Neonatal Calf Diarrhea Virus, Feline Infectious Peritonitis Virus, Canine Coronavirus, Etc.) (424/221.1); Disclosed Amino Acid Sequence Derived From Virus (424/186.1); Conjugate Or Complex Includes Virus Or Component Thereof (424/196.11); Virus Or Component Thereof (424/204.1); Antigens (435/69.3)

International Classification: A61K/3929;